<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TEMODAR - temozolomide capsule </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TEMODAR safely and effectively. See full prescribing information for TEMODAR.<br><br>TEMODAR (temozolomide) Capsules<br>TEMODAR (temozolomide) for Injection administered via intravenous infusion<br>Initial U.S. Approval: 1999</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta"><span class="Bold">Dosage and Administration, Preparation and Administration (<a href="#S2.2">2.2</a>) [02/2011]</span> </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">								TEMODAR is an alkylating drug indicated for the treatment of adult patients with: </p>
<ul>
<li>Newly diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span> (GBM) concomitantly with radiotherapy and then as maintenance treatment. (<a href="#S1.1">1.1</a>)</li>
<li>Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span> patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.  (<a href="#S1.2">1.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>										Newly Diagnosed GBM<span class="Bold">:</span> 75 mg/m<span class="Sup">2</span> for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m<span class="Sup">2</span> once daily for Days 1–5 of a 28-day cycle of TEMODAR for 6 cycles.  (<a href="#S2.1">2.1</a>)</li>
<li>										Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span><span class="Bold">:</span>  Initial dose 150 mg/m<span class="Sup">2</span> once daily for 5 consecutive days per 28-day treatment cycle. (<a href="#S2.1">2.1</a>)</li>
<li>The recommended dose for TEMODAR as an intravenous infusion over 90 minutes is the same as the dose for the oral capsule formulation.  Bioequivalence has been established only when TEMODAR for Injection was given over 90 minutes. (<a href="#S2.1">2.1</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg capsules. (<a href="#S3">3</a>)</li>
<li>100-mg powder for injection. (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any TEMODAR component or to dacarbazine (DTIC). (<a href="#S4.1">4.1</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> - monitor Absolute Neutrophil Count (ANC) and platelet count prior to dosing and throughout treatment.  Geriatric patients and women have a higher risk of developing <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. (<a href="#S5.1">5.1</a>)</li>
<li>Cases of <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> and secondary malignancies, including <span class="product-label-link" type="condition" conceptid="135499" conceptname="Subacute myeloid leukemia">myeloid leukemia</span>, have been observed.  (<a href="#S5.2">5.2</a>)</li>
<li>
<span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP) – prophylaxis required for all patients receiving concomitant TEMODAR and radiotherapy for the 42-day regimen for the treatment of newly diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span>. (<a href="#S5.3">5.3</a>)</li>
<li>All patients, particularly those receiving steroids, should be observed closely for the development of <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> and PCP. (<a href="#S5.4">5.4</a>)</li>
<li>Complete blood counts should be obtained throughout the treatment course as specified. (<a href="#S5.4">5.4</a>)</li>
<li>Fetal harm can occur when administered to a pregnant woman.  Women should be advised to avoid becoming pregnant when receiving TEMODAR. (<a href="#S5.5">5.5</a>)</li>
<li>As bioequivalence has been established only when given over 90 minutes, infusion over a shorter or longer period of time may result in suboptimal dosing; the possibility of an increase in infusion-related adverse reactions cannot be ruled out. (<a href="#S5.6">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>The most common adverse reactions (≥10% incidence) are: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">coordination abnormal</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. (<a href="#S6.1">6.1</a>)</li>
<li>The most common Grade 3 to 4 hematologic laboratory abnormalities (≥10% incidence) that have developed during treatment with temozolomide are: <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. (<a href="#S6.1">6.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> have also been reported. (<a href="#S6">6</a>)</li>
</ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Schering Corporation, a subsidiary of Merck &amp; Co., Inc. at 1-800-526-4099 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>Valproic acid: decreases oral clearance of temozolomide. (<a href="#S7.1">7.1</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Nursing mothers: Not recommended. (<a href="#S8.3">8.3</a>)</li>
<li>Pediatric use: No established use. (<a href="#S8.4">8.4</a>)</li>
<li>Hepatic/<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Caution should be exercised when TEMODAR is administered to patients with severe renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#S8.6">8.6</a>, <a href="#S8.7">8.7</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION, FDA-approved patient labeling, and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Newly Diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">Glioblastoma Multiforme</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing and Dose Modification Guidelines</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation and Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">Myelodysplastic Syndrome</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Laboratory Tests</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Use in Pregnancy</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Infusion Time</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Valproic Acid</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h2><a href="#section-10.1" class="toc"></a></h2>
<h2><a href="#section-10.2" class="toc"></a></h2>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Newly Diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">Glioblastoma Multiforme</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2  Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 Safe Handling and Disposal</a></h2>
<h2><a href="#section-15.2" class="toc">16.2	How Supplied</a></h2>
<h2><a href="#section-15.3" class="toc">16.3	Storage</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information for the Patient</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 FDA-approved Patient Labeling</a></h2>
<h2><a href="#section-20.1" class="toc"></a></h2>
<h2><a href="#section-20.1" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Newly Diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">Glioblastoma Multiforme</span></h2>
<p class="First">TEMODAR<span class="Bold">®</span> (temozolomide) is indicated for the treatment of adult patients with newly diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span> concomitantly with radiotherapy and then as maintenance treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span></h2>
<p class="First">TEMODAR is indicated for the treatment of adult patients with refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span>, i.e., patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing and Dose Modification Guidelines</h2>
<p class="First">The recommended dose for TEMODAR as an intravenous infusion over 90 minutes is the same as the dose for the oral capsule formulation. Bioequivalence has been established only when TEMODAR for Injection was given over 90 minutes  <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.  Dosage of TEMODAR must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and the neutrophil and platelet counts at the time of initiating the next cycle.  For TEMODAR dosage calculations based on body surface area (BSA) see <span class="Bold"><a href="#Table-5">Table 5</a></span>.  For suggested capsule combinations on a daily dose see <span class="Bold"><a href="#Table-6">Table 6</a></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Patients with Newly Diagnosed High Grade <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">Glioma</span>:</span></p>
<p><span class="Italics Underline">Concomitant Phase:</span></p>
<p>TEMODAR is administered at 75 mg/m<span class="Sup">2</span> daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions) followed by maintenance TEMODAR for 6 cycles. Focal RT includes the tumor bed or resection site with a 2- to 3-cm margin. No dose reductions are recommended during the concomitant phase; however, dose interruptions or discontinuation may occur based on toxicity. The TEMODAR dose should be continued throughout the 42-day concomitant period up to 49 days if all of the following conditions are met: absolute neutrophil count ≥1.5 × 10<span class="Sup">9 </span>/L, platelet count ≥100 × 10<span class="Sup">9</span>/L, common toxicity criteria (CTC) nonhematological toxicity ≤Grade 1 (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>). During treatment a complete blood count should be obtained weekly. Temozolomide dosing should be interrupted or discontinued during concomitant phase according to the hematological and nonhematological toxicity criteria as noted in <span class="Bold"><a href="#Table-1">Table 1</a></span>.  PCP prophylaxis is required during the concomitant administration of TEMODAR and radiotherapy and should be continued in patients who develop <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span> until recovery from <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span> (CTC Grade ≤1).</p>
<a name="Table-1"></a><table width="85%">
<caption><span>TABLE 1: Temozolomide Dosing Interruption or Discontinuation During Concomitant Radiotherapy and Temozolomide</span></caption>
<col align="left" valign="bottom" width="38%">
<col align="center" valign="bottom" width="31%">
<col align="center" valign="bottom" width="31%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Toxicity</th>
<th class="Lrule" align="center">TMZ Interruption<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Lrule Rrule" align="center">TMZ Discontinuation</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">TMZ=temozolomide; CTC=Common Toxicity Criteria.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Treatment with concomitant TMZ could be continued when all of the following conditions were met:  absolute neutrophil count ≥1.5 × 10<span class="Sup">9</span>/L; platelet count ≥100 × 10<span class="Sup">9</span>/L; CTC nonhematological toxicity ≤Grade 1 (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>).</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Absolute Neutrophil Count</td>
<td class="Lrule" align="center">≥0.5 and &lt;1.5 × 10<span class="Sup">9</span>/L</td>
<td class="Lrule Rrule" align="center">&lt;0.5 × 10<span class="Sup">9</span>/L</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Platelet Count</td>
<td class="Lrule" align="center">≥10 and &lt;100 × 10<span class="Sup">9</span>/L</td>
<td class="Lrule Rrule" align="center">&lt;10 × 10<span class="Sup">9</span>/L</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">CTC Nonhematological Toxicity<br>(except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>)</td>
<td class="Lrule" align="center">CTC Grade 2</td>
<td class="Lrule Rrule" align="center">CTC Grade 3 or 4</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Maintenance Phase:</span></p>
<p><span class="Italics">Cycle 1: </span></p>
<p>													Four weeks after completing the TEMODAR+RT phase, TEMODAR is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m<span class="Sup">2</span> once daily for 5 days followed by 23 days without treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Cycles 2–6:</span></p>
<p>													At the start of Cycle 2, the dose can be escalated to 200 mg/m<span class="Sup">2</span>, if the CTC nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>), absolute neutrophil count (ANC) is ≥1.5 × 10<span class="Sup">9</span>/L, and the platelet count is ≥100 × 10<span class="Sup">9</span>/L. The dose remains at 200 mg/m<span class="Sup">2</span> per day for the first 5 days of each subsequent cycle except if toxicity occurs.  If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Dose Reduction or Discontinuation During Maintenance: </span></p>
<p>Dose reductions during the maintenance phase should be applied according to <span class="Bold"><a href="#Table-2">Tables 2</a></span> and <span class="Bold"><a href="#Table-3">3</a></span>.</p>
<p>During treatment, a complete blood count should be obtained on Day 22 (21 days after the first dose of TEMODAR) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 10<span class="Sup">9</span>/L (1500/µL) and the platelet count exceeds 100 × 10<span class="Sup">9</span>/L (100,000/µL). The next cycle of TEMODAR should not be started until the ANC and platelet count exceed these levels.  Dose reductions during the next cycle should be based on the lowest blood counts and worst nonhematologic toxicity during the previous cycle. Dose reductions or discontinuations during the maintenance phase should be applied according to <span class="Bold"><a href="#Table-2">Tables 2</a></span> and <span class="Bold"><a href="#Table-3">3</a></span>.</p>
<a name="Table-2"></a><table width="85%">
<caption><span>TABLE 2: Temozolomide Dose Levels for Maintenance Treatment</span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="left" valign="top" width="60%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Dose Level</th>
<th class="Lrule" align="center">Dose (mg/m<span class="Sup">2</span>/day)</th>
<th class="Lrule Rrule" align="center">Remarks</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">−1</td>
<td class="Lrule" align="center">100</td>
<td class="Lrule Rrule" align="left">Reduction for prior toxicity</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">0</td>
<td class="Lrule" align="center">150</td>
<td class="Lrule Rrule" align="left">Dose during Cycle 1</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">1</td>
<td class="Lrule" align="center">200</td>
<td class="Lrule Rrule" align="left">Dose during Cycles 2–6 in absence of toxicity</td>
</tr>
</tbody>
</table>
<a name="Table-3"></a><table width="85%">
<caption><span>TABLE 3: Temozolomide Dose Reduction or Discontinuation During Maintenance Treatment</span></caption>
<col align="left" valign="bottom" width="38%">
<col align="center" valign="bottom" width="31%">
<col align="center" valign="bottom" width="31%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Toxicity</th>
<th class="Lrule" align="center">Reduce TMZ by 1 Dose Level<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</th>
<th class="Lrule Rrule" align="center">Discontinue TMZ</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">TMZ=temozolomide; CTC=Common Toxicity Criteria.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>TMZ dose levels are listed in <span class="Bold"><a href="#Table-2">Table 2</a></span>.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>TMZ is to be discontinued if dose reduction to &lt;100 mg/m<span class="Sup">2</span> is required or if the same Grade 3 nonhematological toxicity (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>) recurs after dose reduction.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Absolute Neutrophil Count</td>
<td class="Lrule" align="center">&lt;1.0 × 10<span class="Sup">9</span>/L</td>
<td class="Lrule Rrule" align="center">See footnote <a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Platelet Count</td>
<td class="Lrule" align="center">&lt;50 × 10<span class="Sup">9</span>/L</td>
<td class="Lrule Rrule" align="center">See footnote <a href="#footnote-3" class="Sup">†</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">CTC Nonhematological Toxicity<br>(except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>)</td>
<td class="Lrule" align="center">CTC Grade 3</td>
<td class="Lrule Rrule" align="center">CTC Grade 4<a href="#footnote-3" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Patients with Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span>: </span></p>
<p>											For adults the initial dose is 150 mg/m<span class="Sup">2</span> once daily for 5 consecutive days per 28-day treatment cycle. For adult patients, if both the nadir and day of dosing (Day 29, Day 1 of next cycle) ANC are ≥1.5 × 10<span class="Sup">9</span>/L (1500/µL) and both the nadir and Day 29, Day 1 of next cycle platelet counts are ≥100 × 10<span class="Sup">9</span>/L (100,000/µL), the TEMODAR dose may be increased to 200 mg/m<span class="Sup">2</span>/day for 5 consecutive days per 28-day treatment cycle. During treatment, a complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 10<span class="Sup">9</span>/L (1500/µL) and the platelet count exceeds 100 × 10<span class="Sup">9</span>/L (100,000/µL). The next cycle of TEMODAR should not be started until the ANC and platelet count exceed these levels. If the ANC <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> to &lt;1.0 × 10<span class="Sup">9</span>/L (1000/µL) or the platelet count is &lt;50 × 10<span class="Sup">9</span>/L (50,000/µL) during any cycle, the next cycle should be reduced by 50 mg/m<span class="Sup">2</span>, but not below 100 mg/m<span class="Sup">2</span>, the lowest recommended dose (see <span class="Bold"><a href="#Table-4">Table 4</a></span>). TEMODAR therapy can be continued until disease progression. In the clinical trial, treatment could be continued for a maximum of 2 years, but the optimum duration of therapy is not known.</p>
<a name="Table-4"></a><table width="65%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">TABLE 4: Dosing Modification Table</span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Table 4: Dosing Modification Table" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=temodar-01.jpg"></td></tr>
</tbody>
</table>
<a name="Table-5"></a><table width="65%">
<caption><span>TABLE 5: Daily Dose Calculations by Body Surface Area (BSA)</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Total BSA<br>(m<span class="Sup">2</span>)</th>
<th class="Lrule" align="center">75 mg/m<span class="Sup">2</span><br>(mg daily)</th>
<th class="Lrule" align="center">150 mg/m<span class="Sup">2</span><br>(mg daily)</th>
<th class="Lrule Rrule" align="center">200 mg/m<span class="Sup">2</span><br>(mg daily)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">1.0</td>
<td class="Lrule" align="center">75</td>
<td class="Lrule" align="center">150</td>
<td class="Lrule Rrule" align="center">200</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.1</td>
<td class="Lrule" align="center">82.5</td>
<td class="Lrule" align="center">165</td>
<td class="Lrule Rrule" align="center">220</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.2</td>
<td class="Lrule" align="center">90</td>
<td class="Lrule" align="center">180</td>
<td class="Lrule Rrule" align="center">240</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.3</td>
<td class="Lrule" align="center">97.5</td>
<td class="Lrule" align="center">195</td>
<td class="Lrule Rrule" align="center">260</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.4</td>
<td class="Lrule" align="center">105</td>
<td class="Lrule" align="center">210</td>
<td class="Lrule Rrule" align="center">280</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.5</td>
<td class="Lrule" align="center">112.5</td>
<td class="Lrule" align="center">225</td>
<td class="Lrule Rrule" align="center">300</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.6</td>
<td class="Lrule" align="center">120</td>
<td class="Lrule" align="center">240</td>
<td class="Lrule Rrule" align="center">320</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.7</td>
<td class="Lrule" align="center">127.5</td>
<td class="Lrule" align="center">255</td>
<td class="Lrule Rrule" align="center">340</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.8</td>
<td class="Lrule" align="center">135</td>
<td class="Lrule" align="center">270</td>
<td class="Lrule Rrule" align="center">360</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">1.9</td>
<td class="Lrule" align="center">142.5</td>
<td class="Lrule" align="center">285</td>
<td class="Lrule Rrule" align="center">380</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">2.0</td>
<td class="Lrule" align="center">150</td>
<td class="Lrule" align="center">300</td>
<td class="Lrule Rrule" align="center">400</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">2.1</td>
<td class="Lrule" align="center">157.5</td>
<td class="Lrule" align="center">315</td>
<td class="Lrule Rrule" align="center">420</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">2.2</td>
<td class="Lrule" align="center">165</td>
<td class="Lrule" align="center">330</td>
<td class="Lrule Rrule" align="center">440</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">2.3</td>
<td class="Lrule" align="center">172.5</td>
<td class="Lrule" align="center">345</td>
<td class="Lrule Rrule" align="center">460</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">2.4</td>
<td class="Lrule" align="center">180</td>
<td class="Lrule" align="center">360</td>
<td class="Lrule Rrule" align="center">480</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">2.5</td>
<td class="Lrule" align="center">187.5</td>
<td class="Lrule" align="center">375</td>
<td class="Lrule Rrule" align="center">500</td>
</tr>
</tbody>
</table>
<a name="Table-6"></a><table width="75%">
<caption><span>TABLE 6: Suggested Capsule Combinations Based on Daily Dose in Adults</span></caption>
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="Botrule First"><th align="left" colspan="7">Number of Daily Capsules by Strength (mg)</th></tr>
<tr class="Last">
<th align="center">Total Daily Dose (mg)</th>
<th align="center">250 mg</th>
<th align="center">180 mg</th>
<th align="center">140 mg</th>
<th align="center">100 mg</th>
<th align="center">20 mg</th>
<th align="center">5 mg</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="center">75</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="center">82.5</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">4</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">90</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">4</td>
<td align="center">2</td>
</tr>
<tr>
<td align="center">97.5</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">105</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">112.5</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="center">120</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">127.5</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">135</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr>
<td align="center">142.5</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">150</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="center">157.5</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">165</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">172.5</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="center">180</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">187.5</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">195</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="center">200</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">210</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="center">220</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">225</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">240</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">255</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">260</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="center">270</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">280</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">285</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">300</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">315</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="center">320</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">330</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="center">340</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">345</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">360</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">375</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="center">380</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">400</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">4</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">420</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">440</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">460</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">480</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td align="center">500</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation and Administration</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">TEMODAR Capsules: </span></p>
<p>In clinical trials, TEMODAR was administered under both fasting and nonfasting conditions; however, absorption is affected by food <span class="Italics">[see <a href="#S12">Clinical Pharmacology (12)</a>]</span>, and consistency of administration with respect to food is recommended. There are no dietary restrictions with TEMODAR. To reduce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, TEMODAR should be taken on an empty stomach. Bedtime administration may be advised. Antiemetic therapy may be administered prior to and/or following administration of TEMODAR.</p>
<p>TEMODAR (temozolomide) Capsules should not be opened or chewed. They should be swallowed whole with a glass of water.</p>
<p>If capsules are accidentally opened or damaged, precautions should be taken to avoid inhalation or contact with the skin or mucous membranes <span class="Italics">[see <a href="#S16.1">How Supplied/Storage and Handling (16.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">TEMODAR for Injection: </span></p>
<p>Each vial of TEMODAR for Injection contains sterile and pyrogen-free temozolomide lyophilized powder. When reconstituted with 41 mL Sterile Water for Injection, the resulting solution will contain 2.5 mg/mL temozolomide. Bring the vial to room temperature prior to reconstitution with Sterile Water for Injection. The vials should be gently swirled and not shaken. Vials should be inspected, and any vial containing visible particulate matter should not be used. Do not further dilute the reconstituted solution. After reconstitution, store at room temperature (25°C [77°F]).  Reconstituted product must be used within 14 hours, including infusion time.</p>
<p style="border-left:1px solid;"><span class="XmChange">Using aseptic technique, withdraw up to 40 mL from each vial to make up the total dose based on <span class="Bold"><a href="#Table-5">Table 5</a></span> above and transfer into an empty 250 mL infusion bag.<span class="Sup">2</span> TEMODAR for Injection should be infused intravenously using a pump over a period of 90 minutes. TEMODAR for Injection should be administered only by intravenous infusion. Flush the lines before and after each TEMODAR infusion.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">TEMODAR for Injection may be administered in the same intravenous line with 0.9% Sodium Chloride injection only.</span></p>
<p>Because no data are available on the compatibility of TEMODAR for Injection with other intravenous substances or additives, other medications should not be infused simultaneously through the same intravenous line.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>TEMODAR (temozolomide) Capsules for oral administration 							<dl class="Circle">
<dt>–</dt>
<dd>5-mg capsules have opaque white bodies with green caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR." </dd>
<dt>–</dt>
<dd>20-mg capsules have opaque white bodies with yellow caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR." </dd>
<dt>–</dt>
<dd>100-mg capsules have opaque white bodies with pink caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR."</dd>
<dt>–</dt>
<dd>140-mg capsules have opaque white bodies with blue caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR."</dd>
<dt>–</dt>
<dd>180-mg capsules have opaque white bodies with orange caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR."</dd>
<dt>–</dt>
<dd>250-mg capsules have opaque white bodies with white caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR."</dd>
</dl>
</li>
<li>TEMODAR (temozolomide) is available as 100-mg/vial powder for injection. The lyophilized powder is white to light tan/light pink. </li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">TEMODAR (temozolomide) is contraindicated in patients who have a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to any of its components. TEMODAR is also contraindicated in patients who have a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to DTIC, since both drugs are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC).</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Patients treated with TEMODAR may experience <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, including prolonged <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, which may result in <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medications associated with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim, complicates assessment.   Prior to dosing, patients must have an absolute neutrophil count (ANC) ≥1.5 × 10<span class="Sup">9</span>/L and a platelet count ≥100 × 10<span class="Sup">9</span>/L. A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 10<span class="Sup">9</span>/L and platelet count exceeds 100 × 10<span class="Sup">9</span>/L. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">Myelodysplastic Syndrome</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> and secondary malignancies, including <span class="product-label-link" type="condition" conceptid="135499" conceptname="Subacute myeloid leukemia">myeloid leukemia</span>, have been observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></h2>
<p class="First">For treatment of newly diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span>: Prophylaxis against <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> is required for all patients receiving concomitant TEMODAR and radiotherapy for the 42-day regimen.</p>
<p>There may be a higher occurrence of PCP when temozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide, particularly patients receiving steroids, should be observed closely for the development of PCP regardless of the regimen.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Laboratory Tests</h2>
<p class="First">For the concomitant treatment phase with RT, a complete blood count should be obtained prior to initiation of treatment and weekly during treatment.</p>
<p>For the 28-day treatment cycles, a complete blood count should be obtained prior to treatment on Day 1 and on Day 22 (21 days after the first dose) of each cycle. Blood counts should be performed weekly until recovery if the ANC <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 1.5 × 10<span class="Sup">9</span>/L and the platelet count <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 100 × 10<span class="Sup">9</span>/L <span class="Italics">[see <a href="#S2.1">Recommended Dosing and Dose Modification Guidelines (2.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Use in Pregnancy</h2>
<p class="First">TEMODAR can cause fetal harm when administered to a pregnant woman.  Administration of TEMODAR to rats and rabbits during organogenesis at 0.38 and 0.75 times the maximum recommended human dose (75 and 150 mg/m<span class="Sup">2</span>), respectively, caused numerous <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> of the external organs, soft tissues, and skeleton in both species <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Infusion Time</h2>
<p class="First">As bioequivalence has been established only when TEMODAR for Injection was given over 90 minutes, infusion over a shorter or longer period of time may result in suboptimal dosing.  Additionally, the possibility of an increase in infusion-related adverse reactions cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Newly Diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">Glioblastoma Multiforme</span>: </span></p>
<p>During the concomitant phase (TEMODAR+radiotherapy), adverse reactions including <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> were more frequent in the TEMODAR+RT arm. The incidence of other adverse reactions was comparable in the two arms. The most common adverse reactions across the cumulative TEMODAR experience were <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (see <span class="Bold"><a href="#Table-7">Table 7</a></span>).  Forty-nine percent (49%) of patients treated with TEMODAR reported one or more severe or life-threatening reactions, most commonly <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (13%), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> (6%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5%), and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (5%).  Overall, the pattern of reactions during the maintenance phase was consistent with the known safety profile of TEMODAR.</p>
<a name="Table-7"></a><table width="100%">
<caption><span>TABLE 7: Number (%) of Patients with Adverse Reactions: All and Severe/Life Threatening (Incidence of 5% or Greater)</span></caption>
<col align="left" valign="middle" width="28%">
<col align="right" valign="middle" width="6%">
<col align="left" valign="middle" width="6%">
<col align="right" valign="middle" width="6%">
<col align="left" valign="middle" width="6%">
<col align="right" valign="middle" width="6%">
<col align="left" valign="middle" width="6%">
<col align="right" valign="middle" width="6%">
<col align="left" valign="middle" width="6%">
<col align="right" valign="middle" width="6%">
<col align="left" valign="middle" width="6%">
<col align="right" valign="middle" width="6%">
<col align="left" valign="middle" width="6%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="4">Concomitant Phase<br>RT Alone<br> (n=285)</th>
<th class="Botrule Rrule" align="center" colspan="4">Concomitant Phase<br>RT+TMZ<br> (n=288)<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</th>
<th class="Botrule Rrule" align="center" colspan="4">Maintenance Phase<br>TMZ<br>(n=224)</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center" colspan="2">All</th>
<th class="Rrule" align="center" colspan="2">Grade ≥3</th>
<th class="Rrule" align="center" colspan="2">All</th>
<th class="Rrule" align="center" colspan="2">Grade ≥3</th>
<th class="Rrule" align="center" colspan="2">All</th>
<th class="Rrule" align="center" colspan="2">Grade ≥3</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="13">RT+TMZ=radiotherapy plus temozolomide; NOS=not otherwise specified.</td></tr>
<tr class="Last"><td align="left" colspan="13">
<span class="Bold">Note</span>: Grade 5 (fatal) adverse reactions are included in the Grade ≥3 column.</td></tr>
<tr><td colspan="13" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>One patient who was randomized to RT only arm received RT+temozolomide.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" valign="bottom"><span class="Bold">Subjects Reporting any Adverse Reaction</span></td>
<td align="right" valign="bottom"><span class="Bold">258 </span></td>
<td class="Rrule" align="left" valign="bottom"><span class="Bold">(91)</span></td>
<td align="right" valign="bottom"><span class="Bold">74 </span></td>
<td class="Rrule" align="left" valign="bottom"><span class="Bold">(26)</span></td>
<td align="right" valign="bottom"><span class="Bold">266 </span></td>
<td class="Rrule" align="left" valign="bottom"><span class="Bold">(92)</span></td>
<td align="right" valign="bottom"><span class="Bold">80 </span></td>
<td class="Rrule" align="left" valign="bottom"><span class="Bold">(28)</span></td>
<td align="right" valign="bottom"><span class="Bold">206 </span></td>
<td class="Rrule" align="left" valign="bottom"><span class="Bold">(92)</span></td>
<td align="right" valign="bottom"><span class="Bold">82 </span></td>
<td class="Rrule" align="left" valign="bottom"><span class="Bold">(37)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Body as a Whole - General Disorders</span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="right">25 </td>
<td class="Rrule" align="left">(9)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">56 </td>
<td class="Rrule" align="left">(19)</td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">61 </td>
<td class="Rrule" align="left">(27)</td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="right">10 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">12 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">12 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="right">139 </td>
<td class="Rrule" align="left">(49)</td>
<td align="right">15 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">156 </td>
<td class="Rrule" align="left">(54)</td>
<td align="right">19 </td>
<td class="Rrule" align="left">(7)</td>
<td align="right">137 </td>
<td class="Rrule" align="left">(61)</td>
<td align="right">20 </td>
<td class="Rrule" align="left">(9)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="right">49 </td>
<td class="Rrule" align="left">(17)</td>
<td align="right">11 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">56 </td>
<td class="Rrule" align="left">(19)</td>
<td align="right">5 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">51 </td>
<td class="Rrule" align="left">(23)</td>
<td align="right">9 </td>
<td class="Rrule" align="left">(4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td align="right">9 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">10 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">5 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">16 </td>
<td class="Rrule" align="left">(7)</td>
<td align="right">4 </td>
<td class="Rrule" align="left">(2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="right">12 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">6 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">11 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">4 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">12 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">4 </td>
<td class="Rrule" align="left">(2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></td>
<td align="right">20 </td>
<td class="Rrule" align="left">(7)</td>
<td align="right">9 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">17 </td>
<td class="Rrule" align="left">(6)</td>
<td align="right">10 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">25 </td>
<td class="Rrule" align="left">(11)</td>
<td align="right">7 </td>
<td class="Rrule" align="left">(3)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory Impairment</span></td>
<td align="right">12 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">8 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">16 </td>
<td class="Rrule" align="left">(7)</td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Disorders of the Eye</span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision Blurred</span></td>
<td align="right">25 </td>
<td class="Rrule" align="left">(9)</td>
<td align="right">4 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">26 </td>
<td class="Rrule" align="left">(9)</td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">17 </td>
<td class="Rrule" align="left">(8)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Disorders of the Immune System</span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></td>
<td align="right">7 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">13 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">6 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Gastrointestinal System Disorders</span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">7 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">11 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="right">18 </td>
<td class="Rrule" align="left">(6)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">53 </td>
<td class="Rrule" align="left">(18)</td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">49 </td>
<td class="Rrule" align="left">(22)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="right">9 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">18 </td>
<td class="Rrule" align="left">(6)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">23 </td>
<td class="Rrule" align="left">(10)</td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="right">45 </td>
<td class="Rrule" align="left">(16)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">105 </td>
<td class="Rrule" align="left">(36)</td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">110 </td>
<td class="Rrule" align="left">(49)</td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td align="right">14 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">19 </td>
<td class="Rrule" align="left">(7)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">20 </td>
<td class="Rrule" align="left">(9)</td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="right">16 </td>
<td class="Rrule" align="left">(6)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">57 </td>
<td class="Rrule" align="left">(20)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">66 </td>
<td class="Rrule" align="left">(29)</td>
<td align="right">4 </td>
<td class="Rrule" align="left">(2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Injury and <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span></span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4085340" conceptname="Radiation injury">Radiation Injury</span> NOS</td>
<td align="right">11 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">20 </td>
<td class="Rrule" align="left">(7)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">5 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal System Disorders</span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">7 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">14 </td>
<td class="Rrule" align="left">(6)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span></span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">11 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">8 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">19 </td>
<td class="Rrule" align="left">(8)</td>
<td align="right">8 </td>
<td class="Rrule" align="left">(4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="right">9 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
<td align="right">14 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">9 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">15 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">19 </td>
<td class="Rrule" align="left">(8)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="right">9 </td>
<td class="Rrule" align="left">(3)</td>
<td align="right">4 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">11 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">5 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">12 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="right">179 </td>
<td class="Rrule" align="left">(63)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">199 </td>
<td class="Rrule" align="left">(69)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">124 </td>
<td class="Rrule" align="left">(55)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span></td>
<td align="right">6 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">7 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">11 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">1 </td>
<td class="Rrule" align="left">(&lt;1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td align="right">15 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">14 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">2 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="right">4 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">11 </td>
<td class="Rrule" align="left">(4)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">11 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="right">42 </td>
<td class="Rrule" align="left">(15)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">56 </td>
<td class="Rrule" align="left">(19)</td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
<td align="right">29 </td>
<td class="Rrule" align="left">(13)</td>
<td align="right">3 </td>
<td class="Rrule" align="left">(1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Special Senses Other, Disorders</span></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
<td align="right"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></td>
<td align="right">6 </td>
<td class="Rrule" align="left">(2)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">18 </td>
<td class="Rrule" align="left">(6)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
<td align="right">11 </td>
<td class="Rrule" align="left">(5)</td>
<td align="right">0 </td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>), which is a known dose-limiting toxicity for most cytotoxic agents, including TEMODAR, was observed. When laboratory abnormalities and adverse reactions were combined, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic reactions were observed in 8% of the patients, and Grade 3 or Grade 4 <span class="product-label-link" type="condition" conceptid="4332151" conceptname="Platelet disorder">platelet abnormalities</span>, including thrombocytopenic reactions, were observed in 14% of the patients treated with TEMODAR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span>: </span></p>
<p><span class="Bold"><a href="#Table-8">Tables 8</a></span> and <span class="Bold"><a href="#Table-9">9</a></span> show the incidence of adverse reactions in the 158 patients in the <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span> study for whom data are available. In the absence of a control group, it is not clear in many cases whether these reactions should be attributed to temozolomide or the patients' underlying conditions, but <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and hematologic effects appear to be clearly drug-related. The most frequently occurring adverse reactions were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. The adverse reactions were usually NCI Common Toxicity Criteria (CTC) Grade 1 or 2 (mild to moderate in severity) and were self-limiting, with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> readily controlled with antiemetics. The incidence of severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (CTC Grade 3 or 4) was 10% and 6%, respectively. <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> (<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>) was the dose-limiting adverse reaction. It usually occurred within the first few cycles of therapy and was not cumulative.</p>
<p><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> occurred late in the treatment cycle and returned to normal, on average, within 14 days of nadir counts. The median nadirs occurred at 26 days for platelets (range: 21–40 days) and 28 days for <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> (range: 1–44 days). Only 14% (22/158) of patients had a neutrophil nadir and 20% (32/158) of patients had a platelet nadir, which may have delayed the start of the next cycle. Less than 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>.</p>
<p>In clinical trial experience with 110 to 111 women and 169 to 174 men (depending on measurements), there were higher rates of Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC&lt;500 cells/µL) and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (&lt;20,000 cells/µL) in women than men in the first cycle of therapy (12% vs. 5% and 9% vs. 3%, respectively).</p>
<p>In the entire safety database for which hematologic data exist (N=932), 7% (4/61) and 9.5% (6/63) of patients over age 70 experienced Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in the first cycle, respectively. For patients less than or equal to age 70, 7% (62/871) and 5.5% (48/879) experienced Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in the first cycle, respectively.  <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> have also been reported.</p>
<a name="Table-8"></a><table width="75%">
<caption><span>TABLE 8: Adverse Reactions in the <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span> Trial in Adults (≥5%)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead>
<tr class="First">
<th align="left"></th>
<th class="Botrule Lrule" align="center" colspan="2">No. (%) of TEMODAR Patients (N=158)</th>
</tr>
<tr>
<th align="left"></th>
<th class="Botrule Lrule Rrule" align="center">All Reactions </th>
<th class="Botrule Toprule" align="center">Grade 3/4</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="left">Any Adverse Reaction </th>
<th class="Rrule" align="center">153 (97)</th>
<th align="center">79 (50)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>; visual deficit; vision changes; vision troubles</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left"><span class="Bold">Body as a Whole</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">65 (41)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">54 (34)</td>
<td align="center">7 (4)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">20 (13)</td>
<td align="center">9 (6)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">21 (13)</td>
<td align="center">3 (2)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">12 (8)</td>
<td align="center">4 (3)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Cardiovascular</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Rrule" align="center">17 (11)</td>
<td align="center">1 (1)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Central and Peripheral Nervous System</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></td>
<td class="Rrule" align="center">36 (23)</td>
<td align="center">8 (5)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">Hemiparesis</span></td>
<td class="Rrule" align="center">29 (18)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">19 (12)</td>
<td align="center">1 (1)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Coordination abnormal</span></td>
<td class="Rrule" align="center">17 (11)</td>
<td align="center">2 (1)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td class="Rrule" align="center">16 (10)</td>
<td align="center">6 (4)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">16 (10)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center">15 (9)</td>
<td align="center">1 (1)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center">15 (9)</td>
<td align="center">5 (3)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">Paresis</span></td>
<td class="Rrule" align="center">13 (8) </td>
<td align="center">4 (3)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span></td>
<td class="Rrule" align="center">13 (8)</td>
<td align="center">3 (2)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Rrule" align="center">12 (8)</td>
<td align="center">3 (2)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Dysphasia</span></td>
<td class="Rrule" align="center">11 (7)</td>
<td align="center">1 (1)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">Convulsions local</span> </td>
<td class="Rrule" align="center">9 (6)</td>
<td align="center"> 0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Gait abnormal</span></td>
<td class="Rrule" align="center"> 9 (6)</td>
<td align="center">1 (1)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Rrule" align="center"> 8 (5)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Endocrine</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="438123" conceptname="Adrenocortical hyperfunction">Adrenal hypercorticism</span></td>
<td class="Rrule" align="center">13 (8)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Gastrointestinal System</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">84 (53)</td>
<td align="center">16 (10)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">66 (42)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">52 (33)</td>
<td align="center">1 (1)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">25 (16)</td>
<td align="center">3 (2)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">14 (9)</td>
<td align="center">2 (1)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">14 (9)</td>
<td align="center">1 (1)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Metabolic</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increase</span></td>
<td class="Rrule" align="center">8 (5)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left">
<span class="Bold">Musculoskeletal System</span><br>
</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center"> 8 (5)</td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule" align="center">11 (7)</td>
<td align="center">1 (1)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">10 (6)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left">
<span class="Bold">Reproductive Disorders</span><br>
</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span>, female</td>
<td class="Rrule" align="center"> 4 (6)</td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Resistance Mechanism Disorders</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection viral</span></td>
<td class="Rrule" align="center">17 (11)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Respiratory System</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">13 (8)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Rrule" align="center">12 (8)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">10 (6)</td>
<td align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td class="Rrule" align="center">8 (5)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Skin and Appendages</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">13 (8)</td>
<td align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">12 (8)</td>
<td align="center">2 (1)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Urinary System</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">12 (8)</td>
<td align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Micturition increased frequency</td>
<td class="Rrule" align="center">9 (6)</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Vision</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></td>
<td class="Rrule" align="center">8 (5)</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision abnormal</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td class="Rrule" align="center">8 (5)</td>
<td align="center"></td>
</tr>
</tbody>
</table>
<a name="Table-9"></a><table width="75%">
<caption><span>TABLE 9: Adverse Hematologic Effects (Grade 3 to 4) in the <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span> Trial in Adults</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center">TEMODAR<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Change from Grade 0 to 2 at baseline to Grade 3 or 4 during treatment.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Hemoglobin</td>
<td class="Rrule" align="center">7/158 (4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Rrule" align="center">83/152 (55%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td class="Rrule" align="center">20/142 (14%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Platelets</td>
<td class="Rrule" align="center">29/156 (19%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">WBC</td>
<td class="Rrule" align="center">18/158 (11%)</td>
</tr>
</tbody>
</table>
<p>TEMODAR for injection delivers equivalent temozolomide dose and exposure to both temozolomide and 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC) as the corresponding TEMODAR capsules. Adverse reactions probably related to treatment that were reported from the 2 studies with the intravenous formulation (n=35) that were not reported in studies using the TEMODAR capsules were: <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, irritation, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, warmth, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> at infusion site as well as the following adverse reactions: <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of TEMODAR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug exposure.</p>
<p>TEMODAR Capsules: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported.  <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> has been reported, which resolved after discontinuation of TEMODAR and, in some cases, recurred upon rechallenge.  Cases of <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> have been reported.</p>
<p>There have been reported cases of hepatotoxicity, including elevations of liver enzymes, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic infections</span> including <span class="Italics">Pneumocystis carinii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP) have also been reported. Cases of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>/<span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, alveolitis, and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span> have been reported. Prolonged <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, which may result in <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, has been reported, and in some cases has resulted in a fatal outcome.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Valproic Acid</h2>
<p class="First">Administration of valproic acid decreases oral clearance of temozolomide by about 5%. The clinical implication of this effect is not known <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Pregnancy Category D. See <a href="#S5">Warnings and Precautions</a> section.</span></p>
<p> TEMODAR can cause fetal harm when administered to a pregnant woman. Five consecutive days of oral temozolomide administration of 0.38 and 0.75 times the highest recommended human dose (75 and 150 mg/m<span class="Sup">2</span>) in rats and rabbits, respectively, during the period of organogenesis caused numerous malformations of the external and internal soft tissues and skeleton in both species. Doses equivalent to 0.75 times the highest recommended human dose (150 mg/m<span class="Sup">2</span>) caused embryolethality in rats and rabbits as indicated by increased resorptions. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.  Women of childbearing potential should be advised to avoid becoming pregnant during therapy with TEMODAR.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants and tumorigenicity shown for temozolomide in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother from TEMODAR.  </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. TEMODAR Capsules have been studied in 2 open-label studies in pediatric patients (aged 3–18 years) at a dose of 160 to 200 mg/m<span class="Sup">2</span> daily for 5 days every 28 days. In one trial, 29 patients with recurrent brain stem <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">glioma</span> and 34 patients with recurrent high grade <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytoma</span> were enrolled. All patients had recurrence following surgery and radiation therapy, while 31% also had disease progression following chemotherapy.  In a second study conducted by the Children's Oncology Group (COG), 122 patients were enrolled, including patients with <span class="product-label-link" type="condition" conceptid="4306469" conceptname="Medulloblastoma">medulloblastoma</span>/PNET (29), high grade <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytoma</span> (23), low grade <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytoma</span> (22), brain stem <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">glioma</span> (16), <span class="product-label-link" type="condition" conceptid="4239952" conceptname="Ependymoma">ependymoma</span> (14), other CNS tumors (9), and non-CNS tumors (9).  The TEMODAR toxicity profile in pediatric patients is similar to adults.  <span class="Bold">Table 10</span> shows the adverse reactions in 122 children in the COG study.</p>
<a name="Table-10"></a><table width="80%">
<caption><span>TABLE 10: Adverse Reactions Reported in the Pediatric Cooperative Group Trial  (≥10%)</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th align="left"></th>
<th align="center" colspan="2">No. (%) of TEMODAR Patients<br>											 (N=122)<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</th>
</tr>
<tr>
<th align="left">Body System/Organ Class</th>
<th class="Lrule" align="center">All Reactions</th>
<th class="Lrule" align="center">Grade 3/4</th>
</tr>
<tr class="Last">
<th align="left">         Adverse Reaction</th>
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>These various tumors included the following: PNET-<span class="product-label-link" type="condition" conceptid="4306469" conceptname="Medulloblastoma">medulloblastoma</span>, <span class="product-label-link" type="condition" conceptid="4272187" conceptname="Glioblastoma">glioblastoma</span>, low grade <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytoma</span>, brain stem tumor, <span class="product-label-link" type="condition" conceptid="4239952" conceptname="Ependymoma">ependymoma</span>, mixed <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">glioma</span>, <span class="product-label-link" type="condition" conceptid="40484128" conceptname="Oligodendroglioma">oligodendroglioma</span>, <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span>, Ewing's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, pineoblastoma, alveolar soft part <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, neurofibrosarcoma, optic <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">glioma</span>, and <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">Subjects Reporting an AE</span></td>
<td class="Lrule" align="center"><span class="Bold">107 (88)</span></td>
<td class="Lrule" align="center"><span class="Bold">69 (57)</span></td>
</tr>
<tr>
<td align="left"><span class="Bold">Body as a Whole</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Central and Peripheral Nervous System</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
</tr>
<tr>
<td align="left">Central cerebral CNS cortex</td>
<td class="Lrule" align="center">22 (18)</td>
<td class="Lrule" align="center">13 (11)</td>
</tr>
<tr>
<td align="left"><span class="Bold">Gastrointestinal System</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule" align="center">56 (46)</td>
<td class="Lrule" align="center">5 (4)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">62 (51)</td>
<td class="Lrule" align="center">4 (3)</td>
</tr>
<tr>
<td align="left"><span class="Bold">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and Clotting</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Lrule" align="center">71 (58)</td>
<td class="Lrule" align="center">31 (25)</td>
</tr>
<tr>
<td align="left"><span class="Bold">Red Blood Cell Disorders</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Decreased Hemoglobin</span></td>
<td class="Lrule" align="center">62 (51)</td>
<td class="Lrule" align="center">7 (6)</td>
</tr>
<tr>
<td align="left"><span class="Bold">White Cell and RES Disorders</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
</tr>
<tr>
<td align="left">Decreased WBC</td>
<td class="Lrule" align="center">71 (58)</td>
<td class="Lrule" align="center">21 (17)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Lrule" align="center">73 (60)</td>
<td class="Lrule" align="center">48 (39)</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Lrule" align="center">62 (51)</td>
<td class="Lrule" align="center">24 (20)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of temozolomide did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>In the <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span> study population, patients 70 years of age or older had a higher incidence of Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and Grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (2/8; 25%, <span class="Italics">P</span>=0.31 and 2/10; 20%, <span class="Italics">P</span>=0.09, respectively) in the first cycle of therapy than patients under 70 years of age <span class="Italics">[see <a href="#S5">Warnings and Precautions (5)</a> and <a href="#S6">Adverse Reactions (6)</a>].</span></p>
<p>In newly diagnosed patients with <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span>, the adverse reaction profile was similar in younger patients (&lt;65 years) vs. older (≥65 years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Caution should be exercised when TEMODAR is administered to patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Caution should be exercised when TEMODAR is administered to patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Doses of 500, 750, 1000, and 1250 mg/m<span class="Sup">2 </span>(total dose per cycle over 5 days) have been evaluated clinically in patients.  Dose-limiting toxicity was hematologic and was reported with any dose but is expected to be more severe at higher doses.  An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of 2000 mg per day for 5 days was taken by one patient and the adverse reactions reported were <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, multi-organ failure, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. There are reports of patients who have taken more than 5 days of treatment (up to 64 days), with adverse reactions reported including bone marrow suppression, which in some cases was severe and prolonged, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, hematologic evaluation is needed.  Supportive measures should be provided as necessary.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">TEMODAR contains temozolomide, an imidazotetrazine derivative. The chemical name of temozolomide is 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-<span class="Italics">a</span>s-tetrazine-8-carboxamide. The structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=temodar-02.jpg"></div>
<p>The material is a white to light tan/light pink powder with a molecular formula of C<span class="Sub">6</span>H<span class="Sub">6</span>N<span class="Sub">6</span>O<span class="Sub">2</span> and a molecular weight of 194.15. The molecule is stable at acidic pH (&lt;5) and labile at pH &gt;7; hence TEMODAR can be administered orally and intravenously. The prodrug, temozolomide, is rapidly hydrolyzed to the active 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis taking place even faster at alkaline pH.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold Italics">TEMODAR Capsules: </span></p>
<p>									Each capsule for oral use contains either 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg of temozolomide.</p>
<p> The inactive ingredients for TEMODAR Capsules are as follows:</p>
<dl>
<dt> </dt>
<dd>
<span class="Italics"> TEMODAR 5 mg</span>: lactose anhydrous (132.8 mg), colloidal silicon dioxide (0.2 mg), sodium starch glycolate (7.5 mg), tartaric acid (1.5 mg), and stearic acid (3 mg). </dd>
<dt> </dt>
<dd>
<span class="Italics"> TEMODAR 20 mg</span>: lactose anhydrous (182.2 mg), colloidal silicon dioxide (0.2 mg), sodium starch glycolate (11 mg), tartaric acid (2.2 mg), and stearic acid (4.4 mg).</dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 100 mg</span>: lactose anhydrous (175.7 mg), colloidal silicon dioxide (0.3 mg), sodium starch glycolate (15 mg), tartaric acid (3 mg), and stearic acid (6 mg).</dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 140 mg:</span> lactose anhydrous (246 mg), colloidal silicon dioxide (0.4 mg), sodium starch glycolate (21 mg), tartaric acid (4.2 mg), and stearic acid (8.4 mg). </dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 180 mg</span>: lactose anhydrous (316.3 mg), colloidal silicon dioxide (0.5 mg), sodium starch glycolate (27 mg), tartaric acid (5.4 mg), and stearic acid (10.8 mg). </dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 250 mg</span>: lactose anhydrous (154.3 mg), colloidal silicon dioxide (0.7 mg), sodium starch glycolate (22.5 mg), tartaric acid (9 mg), and stearic acid (13.5 mg). </dd>
</dl>
<p>The body of the capsules are made of gelatin, and are opaque white. The cap is also made of gelatin, and the colors vary based on the dosage strength. The capsule body and cap are imprinted with pharmaceutical branding ink, which contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, purified water, strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution, potassium hydroxide, and ferric oxide.</p>
<dl>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 5 mg:</span> The green cap contains gelatin, titanium dioxide, iron oxide yellow, sodium lauryl sulfate, and FD&amp;C Blue #2.</dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 20 mg:</span> The yellow cap contains gelatin, sodium lauryl sulfate, and iron oxide yellow.</dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 100 mg:</span> The pink cap contains gelatin, titanium dioxide, sodium lauryl sulfate, and iron oxide red.</dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 140 mg:</span> The blue cap contains gelatin, sodium lauryl sulfate, and FD&amp;C Blue #2.</dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 180 mg:</span> The orange cap contains gelatin, iron oxide red, iron oxide yellow, titanium dioxide, and sodium lauryl sulfate.</dd>
<dt> </dt>
<dd>
<span class="Italics">TEMODAR 250 mg:</span> The white cap contains gelatin, titanium dioxide, and sodium lauryl sulfate.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold Italics">TEMODAR for Injection: </span></p>
<p>									 Each vial contains 100 mg of sterile and pyrogen-free temozolomide lyophilized powder for intravenous injection.  The inactive ingredients are: mannitol (600 mg), L-threonine (160 mg), polysorbate 80 (120 mg), sodium citrate dihydrate (235 mg), and hydrochloric acid (160 mg). </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC).  The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA.  Alkylation (methylation) occurs mainly at the O<span class="Sup">6</span> and N<span class="Sup">7</span> positions of guanine.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Absorption: </span></p>
<p>Temozolomide is rapidly and completely absorbed after oral administration with a peak plasma concentration (C<span class="Sub">max</span>) achieved in a median T<span class="Sub">max</span> of 1 hour. Food reduces the rate and extent of temozolomide absorption. Mean peak plasma concentration and AUC decreased by 32% and 9%, respectively, and median T<span class="Sub">max</span> increased by 2-fold (from 1–2.25 hours) when temozolomide was administered after a modified high-fat breakfast. </p>
<p>A pharmacokinetic study comparing oral and intravenous temozolomide in 19 patients with primary CNS malignancies showed that 150 mg/m<span class="Sup">2</span> TEMODAR for injection administered over 90 minutes is bioequivalent to 150 mg/m<span class="Sup">2</span> TEMODAR oral capsules with respect to both C<span class="Sub">max</span> and AUC of temozolomide and MTIC.  Following a single 90-minute intravenous infusion of 150 mg/m<span class="Sup">2</span>, the geometric mean C<span class="Sub">max</span> values for temozolomide and MTIC were 7.3 mcg/mL and 276 ng/mL, respectively. Following a single oral dose of 150 mg/m<span class="Sup">2,</span> the geometric mean C<span class="Sub">max</span> values for temozolomide and MTIC were 7.5 mcg/mL and 282 ng/mL, respectively.  Following a single 90-minute intravenous infusion of 150 mg/m<span class="Sup">2</span>, the geometric mean AUC values for temozolomide and MTIC were 24.6 mcg∙hr/mL and 891 ng∙hr/mL, respectively. Following a single oral dose of 150 mg/m<span class="Sup">2</span>, the geometric mean AUC values for temozolomide and MTIC were 23.4 mcg∙hr/mL and 864 ng∙hr/mL, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Distribution: </span></p>
<p>Temozolomide has a mean apparent volume of distribution of 0.4 L/kg (%CV=13%). It is weakly bound to human plasma proteins; the mean percent bound of drug-related total radioactivity is 15%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Metabolism and Elimination: </span></p>
<p>											 Temozolomide is spontaneously hydrolyzed at physiologic pH to the active species, MTIC and to temozolomide acid metabolite. MTIC is further hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), which is known to be an intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species. Cytochrome P450 enzymes play only a minor role in the metabolism of temozolomide and MTIC. Relative to the AUC of temozolomide, the exposure to MTIC and AIC is 2.4% and 23%, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Excretion: </span></p>
<p>About 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 37.7% in urine and 0.8% in feces. The majority of the recovery of radioactivity in urine is unchanged temozolomide (5.6%), AIC (12%), temozolomide acid metabolite (2.3%), and unidentified polar metabolite(s) (17%). Overall clearance of temozolomide is about 5.5 L/hr/m<span class="Sup">2</span>. Temozolomide is rapidly eliminated, with a mean elimination half-life of 1.8 hours, and exhibits linear kinetics over the therapeutic dosing range of 75 to 250 mg/m<span class="Sup">2</span>/day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Effect of Age: </span></p>
<p>A population pharmacokinetic analysis indicated that age (range: 19–78 years) has no influence on the pharmacokinetics of temozolomide. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Effect of Gender: </span></p>
<p>A population pharmacokinetic analysis indicated that women have an approximately 5% lower clearance (adjusted for body surface area) for temozolomide than men. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Effect of Race: </span></p>
<p>The effect of race on the pharmacokinetics of temozolomide has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.8"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Tobacco Use: </span></p>
<p>A population pharmacokinetic analysis indicated that the oral clearance of temozolomide is similar in smokers and <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.9"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span></p>
<p>A population pharmacokinetic analysis indicated that creatinine clearance over the range of 36 to 130 mL/min/m<span class="Sup">2</span> has no effect on the clearance of temozolomide after oral administration. The pharmacokinetics of temozolomide have not been studied in patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (CLcr &lt;36 mL/min/m<span class="Sup">2</span>). Caution should be exercised when TEMODAR is administered to patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S8.6">Use in Special Populations (8.6)</a>]</span>. TEMODAR has not been studied in patients on dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.10"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span></p>
<p>A study showed that the pharmacokinetics of temozolomide in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class I – II) were similar to those observed in patients with normal hepatic function. Caution should be exercised when temozolomide is administered to patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S8.7">Use in Special Populations (8.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.11"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Effect of Other Drugs on Temozolomide Pharmacokinetics:  </span></p>
<p>In a multiple-dose study, administration of TEMODAR Capsules with ranitidine did not change the C<span class="Sub">max</span> or AUC values for temozolomide or MTIC.</p>
<p>A population analysis indicated that administration of valproic acid decreases the clearance of temozolomide by about 5% <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>].</span></p>
<p>A population analysis did not demonstrate any influence of coadministered dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, H<span class="Sub">2</span>-receptor antagonists, or phenobarbital on the clearance of orally administered temozolomide.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Temozolomide is carcinogenic in rats at doses less than the maximum recommended human dose.  Temozolomide induced mammary carcinomas in both males and females at doses 0.13 to 0.63 times the maximum human dose (25–125 mg/m<span class="Sup">2</span>) when administered orally on 5 consecutive days every 28 days for 6 cycles.  Temozolomide also induced <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcomas</span> of the heart, eye, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, salivary glands, abdominal cavity, uterus, and prostate, carcinomas of the seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, schwannomas of the heart, optic nerve, and harderian gland, and <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the skin, lung, pituitary, and thyroid at doses 0.5 times the maximum daily dose. Mammary tumors were also induced following 3 cycles of temozolomide at the maximum recommended daily dose.  </p>
<p>Temozolomide is a mutagen and a clastogen.  In a reverse bacterial mutagenesis assay (Ames assay), temozolomide increased revertant frequency in the absence and presence of metabolic activation.  Temozolomide was clastogenic in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in the presence and absence of metabolic activation.  </p>
<p>Temozolomide impairs male fertility.  Temozolomide caused syncytial cells/immature sperm formation at 0.25 and 0.63 times  the maximum recommended human dose (50 and 125 mg/m<span class="Sup">2</span>) in rats and dogs, respectively, and <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> in dogs at 0.63 times the maximum recommended human dose (125 mg/m<span class="Sup">2</span>). </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Toxicology studies in rats and dogs identified a low incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, degeneration, and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of the retina at temozolomide doses equal to or greater than 0.63 times the maximum recommended human dose (125 mg/m<span class="Sup">2</span>). These changes were most commonly seen at doses where mortality was observed. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Newly Diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">Glioblastoma Multiforme</span></h2>
<p class="First">Five hundred and seventy-three patients were randomized to receive either TEMODAR (TMZ)+Radiotherapy (RT) (n=287) or RT alone (n=286).  Patients in the TEMODAR+RT arm received concomitant TEMODAR (75 mg/m<span class="Sup">2</span> ) once daily, starting the first day of RT until the last day of RT, for 42 days (with a maximum of 49 days).  This was followed by 6 cycles of TEMODAR alone (150 or 200 mg/m<span class="Sup">2</span>) on Days 1 to 5 of every 28-day cycle, starting 4 weeks after the end of RT. Patients in the control arm received RT only. In both arms, focal radiation therapy was delivered as 60 Gy/30 fractions. Focal RT includes the tumor bed or resection site with a 2- to 3-cm margin. <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP) prophylaxis was required during the TMZ + RT, regardless of lymphocyte count, and was to continue until recovery of lymphocyte count to less than or equal to Grade 1.</p>
<p>At the time of disease progression, TEMODAR was administered as salvage therapy in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TEMODAR+RT arm.</p>
<p>The addition of concomitant and maintenance TEMODAR to radiotherapy in the treatment of patients with newly diagnosed GBM showed a statistically significant improvement in overall survival compared to radiotherapy alone (<span class="Bold"><a href="#figure1">Figure 1</a></span>). The hazard ratio (HR) for overall survival was 0.63 (95% CI for HR=0.52-0.75) with a log-rank <span class="Italics">P</span>&lt;0.0001 in favor of the TEMODAR arm. The median survival was increased by 2.5 months in the TEMODAR arm.<br> </p>
<p><span class="Bold">FIGURE 1: Kaplan-Meier Curves for Overall Survival (ITT Population)</span></p>
<p><a name="figure1"></a><img alt="FIGURE 1: Kaplan-Meier Curves for Overall Survival (ITT Population)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=temodar-03.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2  Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span></h2>
<p class="First">A single-arm, multicenter study was conducted in 162 patients who had <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span> at first relapse and who had a baseline Karnofsky performance status of 70 or greater. Patients had previously received radiation therapy and may also have previously received a nitrosourea with or without other chemotherapy. Fifty-four patients had disease progression on prior therapy with both a nitrosourea and procarbazine, and their malignancy was considered refractory to chemotherapy (refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span> population). Median age of this subgroup of 54 patients was 42 years (19–76). Sixty-five percent were male. Seventy-two percent of patients had a KPS of &gt;80. Sixty-three percent of patients had surgery other than a biopsy at the time of initial diagnosis. Of those patients undergoing resection, 73% underwent a subtotal resection and 27% underwent a gross total resection. Eighteen percent of patients had surgery at the time of first relapse. The median time from initial diagnosis to first relapse was 13.8 months (4.2–75.4).</p>
<p>TEMODAR Capsules were given for the first 5 consecutive days of a 28-day cycle at a starting dose of 150 mg/m<span class="Sup">2</span>/day. If the nadir and day of dosing (Day 29, Day 1 of next cycle) absolute neutrophil count was ≥1.5 × 10<span class="Sup">9</span>/L (1500/µL) and the nadir and Day 29, Day 1 of next cycle platelet count was ≥100 × 10<span class="Sup">9</span>/L (100,000/µL), the TEMODAR dose was increased to 200 mg/m<span class="Sup">2</span>/day for the first 5 consecutive days of a 28-day cycle.</p>
<p>In the refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span> population, the overall tumor response rate (CR + PR) was 22% (12/54 patients) and the complete response rate was 9% (5/54 patients). The median duration of all responses was 50 weeks (range: 16–114 weeks) and the median duration of complete responses was 64 weeks (range:52–114 weeks). In this population, progression-free survival at 6 months was 45% (95% CI: 31%–58%) and progression-free survival at 12 months was 29% (95% CI: 16%–42%). Median progression-free survival was 4.4 months. Overall survival at 6 months was 74% (95% CI: 62%–86%) and 12-month overall survival was 65% (95% CI: 52%–78%). Median overall survival was 15.9 months.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI:   Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA,   1999.</li>
<li>American   Society of Health-System Pharmacists. ASHP guidelines on handling   hazardous drugs. <span class="Italics">Am J Health-Syst Pharm.</span> 2006; 63:1172–1193.</li>
<li>NIOSH   Alert: Preventing occupational exposures to antineoplastic and other   hazardous drugs in healthcare settings. 2004. U.S. Department of Health   and Human Services, Public Health Service, Centers for Disease Control and   Prevention, National Institute for Occupational Safety and Health, DHHS   (NIOSH) Publication No. 2004-165.[3]</li>
<li>Polovich, M., White, J. M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and   biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-15.1"></a><p></p>
<h2>16.1 Safe Handling and Disposal</h2>
<p class="First">Care should be exercised in the handling and preparation of TEMODAR. Vials and capsules should not be opened. If vials or capsules are accidentally opened or damaged, rigorous precautions should be taken with the contents to avoid inhalation or contact with the skin or mucous membranes.  The use of gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial or capsules.  Procedures for proper handling and disposal of anticancer drugs should be considered<span class="Sup">1–4</span>.  Several guidelines on this subject have been published.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.2"></a><a name="section-15.2"></a><p></p>
<h2>16.2	How Supplied</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">TEMODAR Capsules: </span></p>
<p>TEMODAR (temozolomide) Capsules are supplied in amber glass bottles with child-resistant polypropylene caps containing the following capsule strengths:</p>
<p><span class="Italics">TEMODAR Capsules 5 mg:</span> have opaque white bodies with green caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR".<br>						They are supplied as follows:<br>						  5-count - NDC 54868-5348-1</p>
<p><span class="Italics">TEMODAR Capsules 20 mg:</span> have opaque white bodies with yellow caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR". <br>They are supplied as follows: <br>						  5-count - NDC 54868-4142-0<br>						  10-count - NDC 54868-4142-2<br>						  20-count - NDC 54868-4142-6<br>						  30-count - NDC 54868-4142-5<br>						  40-count - NDC 54868-4142-4<br>						  60-count - NDC 54868-4142-3</p>
<p><span class="Italics">TEMODAR Capsules 100 mg:</span> have opaque white bodies with pink caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR".<br>They are supplied as follows:<br>						  5-count - NDC 54868-5350-2<br>						  10-count - NDC 54868-5350-3<br>						  15-count - NDC 54868-5350-0<br>						  30-count - NDC 54868-5350-4</p>
<p><span class="Italics">TEMODAR Capsules 180 mg:</span> have opaque white bodies with orange caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR".<br>						They are supplied as follows: <br>						  14-count - NDC 54868-5980-0</p>
<p><span class="Italics">TEMODAR Capsules 250 mg:</span> have opaque white bodies with white caps. The capsule body is imprinted with two stripes, the dosage strength, and the Schering-Plough logo.  The cap is imprinted with "TEMODAR". <br>They are supplied as follows: <br>						  5-count - NDC 54868-5354-0</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics"></span></p>
<p></p>
<p><span class="Italics"></span><br></p>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.3"></a><a name="section-15.3"></a><p></p>
<h2>16.3	Storage</h2>
<p class="First"><span class="Bold">Store TEMODAR Capsules at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F)</span></p>
<p><span class="Bold">[see USP Controlled Room Temperature].</span></p>
<p><span class="Bold">Store TEMODAR for Injection refrigerated at 2°–8°C (36°–46°F). After reconstitution, store reconstituted product at room temperature (25°C [77°F]). Reconstituted product must be used within 14 hours, including infusion time.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Information for the Patient</h2>
<p class="First">Physicians should discuss the following with their patients:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are the most frequently occurring adverse reactions. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are usually either self-limiting or readily controlled with standard antiemetic therapy. </li>
<li>Capsules should not be opened. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes. </li>
<li>The medication should be kept away from children and pets.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2>17.2 FDA-approved Patient Labeling</h2>
<p class="First"> </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Underline">TEMODAR Capsules</span><br>Manufactured 
by: Schering Corporation, a subsidiary of <span class="Bold">{corporate logo}MERCK 
&amp; CO., INC.</span>, Whitehouse Station, NJ 08889, USA</p>
<p><span class="Underline">TEMODAR for Injection</span><br>Manufactured by: 
Baxter Oncology GmbH, Halle/Westfalen, Germany <br>Distributed by: Schering 
Corporation, a subsidiary of <span class="Bold">{corporate logo}MERCK &amp; CO., 
INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Copyright© 1999, 2008 Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span> All rights reserved.</p>
<p>TEMODAR Capsules: U.S. Patent No. 5,260,291<br>TEMODAR for Injection: US 
Patent Nos. 5,260,291; 6,987,108; 7,786,118</p>
<p>31850940T<br>Rev 2/11</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First">Tear patient package insert at perforation and give to patient.</p>
<p><span class="Bold">Patient Package Insert</span><br><span class="Bold">TEMODAR<span class="Sup">®</span> (tĕm-?-dăr) </span><br><span class="Bold">(temozolomide) </span><br><span class="Bold">Capsules </span><br><span class="Bold">TEMODAR<span class="Sup">®</span> (tĕm-?-dăr) </span><br><span class="Bold">for Injection</span></p>
<p><span class="Bold">What is the most important information I should know about TEMODAR?</span></p>
<ul><li>
<span class="Bold">TEMODAR may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span></span>. Male and female patients who take TEMODAR should use effective birth control. Female patients and female partners of male patients should avoid becoming pregnant while taking TEMODAR.</li></ul>
<p><span class="Bold">See the section "<a href="#What">What are the possible side effects of TEMODAR?</a>" for more information about side effects.</span></p>
<p><span class="Bold">What is TEMODAR?</span></p>
<p>TEMODAR (temozolomide) is a prescription medicine used to treat adults with certain brain cancer tumors. TEMODAR blocks cell growth, especially cells that grow fast, such as cancer cells. TEMODAR may decrease the size of certain <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumors</span> in some patients.</p>
<p>It is not known if TEMODAR is safe and effective in children.</p>
<p><span class="Bold">Who should not take TEMODAR?</span></p>
<p><span class="Bold">Do not take TEMODAR if you:</span></p>
<ul>
<li>have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to DTIC (dacarbazine), another cancer medicine.</li>
<li>have had a red <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, such as trouble breathing, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, throat, or tongue, or severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> to TEMODAR or any of the ingredients in TEMODAR. If you are not sure, ask your doctor. See the end of the leaflet for a list of ingredients in TEMODAR.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking TEMODAR?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions, including if you:</span></p>
<ul>
<li>are allergic to DTIC (dacarbazine) or have had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to TEMODAR. See "<a href="#Who">Who should not take TEMODAR?</a>"</li>
<li>have kidney problems</li>
<li>have liver problems</li>
<li>are pregnant. See "<a href="#Important">What is the most important information I should know about TEMODAR?</a>"</li>
<li>are breast-feeding. It is not known whether TEMODAR passes into breast milk. You and your doctor should decide if you will breast-feed or take TEMODAR.  You should not do both without talking with your doctor. </li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take a medicine that contains valproic acid (Stavzor<span class="Sup">®</span>, Depakene<span class="Sup">®)</span>.</p>
<p>Know the medicines you take.  Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take TEMODAR?  </span></p>
<p>Temodar may be taken by mouth as a capsule at home, or you may receive TEMODAR by injection into a vein (intravenous).  Your doctor will decide the best way for you to take TEMODAR.</p>
<p>There are two common dosing schedules for taking TEMODAR.  </p>
<ul>
<li>Some people take TEMODAR for 42 days in a row (possibly 49 days depending on side effects) with radiation treatment.  This is one cycle of treatment.  After this, you may have "maintenance" treatment. Your doctor may prescribe 6 more cycles of TEMODAR. For each of these cycles, you take TEMODAR one time each day for 5 days in a row and then you stop taking it for the next 23 days. This is a 28-day maintenance treatment cycle. </li>
<li>Another way to take TEMODAR is to take it one time each day for 5 days in a row only, and then you stop taking it for the next 23 days. This is one cycle of treatment (28 days).  Your doctor will watch your progress on TEMODAR and decide how long you should take it.  You might take TEMODAR until your tumor gets worse or for possibly up to 2 years.  </li>
<li>Your dose is based on your height and weight, and the number of treatment cycles will depend on how you respond to and tolerate this treatment.</li>
<li>Your doctor may modify your schedule based on how you tolerate the treatment.</li>
<li>If your doctor prescribes a treatment regimen that is different from the information in this leaflet, make sure you follow the specific instructions given to you by your doctor.</li>
</ul>
<p><span class="Bold Italics">TEMODAR Capsules:</span></p>
<ul>
<li>Take TEMODAR Capsules exactly as prescribed.  </li>
<li>TEMODAR Capsules come in different strengths. Each strength has a different color cap. Your doctor may prescribe more than one strength of TEMODAR Capsules for you, so it is important that you understand how to take your medicine the right way.  Be sure that you understand exactly how many capsules you need to take on each day of your treatment, and what strengths to take. This may be different whenever you start a new cycle.</li>
<li>Talk to your doctor before you take your dose if you are not sure how much to take.  This will help to prevent taking too much TEMODAR and decrease your chances of getting serious side effects.</li>
<li>Take each day's dose of TEMODAR Capsules at one time, with a full glass of water.</li>
<li><span class="Bold">Swallow TEMODAR Capsules whole.  Do not chew, open, or split the capsules.</span></li>
<li>If TEMODAR capsules are accidentally opened or damaged, be careful not to breathe in (inhale) the powder from the capsules or get the powder on your skin or mucous membranes (for example, in your nose or mouth). If contact with any of these areas happens, flush the area with water.</li>
<li>If you vomit TEMODAR Capsules, do not take any more capsules. Wait and take your next planned dose. </li>
<li>The medicine is used best by your body if you take it at the same time every day in relation to a meal.</li>
<li>To lessen <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, try to take TEMODAR on an empty stomach or at bedtime. Your doctor may prescribe medicine to prevent or treat <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or other medicines to lessen side effects with TEMODAR. </li>
<li>See your doctor regularly to check your progress. Your doctor will check you for side effects that you might not notice.</li>
<li>If you miss a dose of TEMODAR, talk with your doctor for instructions about when to take your next dose of TEMODAR. </li>
<li>Call your doctor right away if you take more than the prescribed amount of TEMODAR. It is important that you do not take more than the amount of TEMODAR prescribed for you.</li>
</ul>
<p><span class="Bold Italics">TEMODAR for Injection:</span></p>
<ul>
<li>You will receive TEMODAR as an infusion directly into your vein.  Your treatment will take about 90 minutes.</li>
<li>Your doctor may prescribe medicine to prevent or treat <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or other medicines to relieve side effects with TEMODAR.</li>
</ul>
<p><span class="Bold">What should I avoid while taking TEMODAR?</span></p>
<ul><li>Female patients and female partners of male patients should avoid becoming pregnant while taking TEMODAR.  See "<a href="#important">What is the most important information I should know about TEMODAR?</a>"</li></ul>
<p><span class="Bold">What are the possible side effects of TEMODAR?</span></p>
<p><span class="Bold">TEMODAR can cause serious side effects.</span></p>
<ul>
<li>See "<a href="#important">What is the most important information I should know about TEMODAR?</a>"</li>
<li>
<span class="Bold">Decreased blood cells</span>.  TEMODAR affects cells that grow rapidly, including bone marrow cells.  This can cause you to have a decrease in blood cells. Your doctor can monitor your blood for these effects.  							 							 							<ul class="Circle">
<li>White blood cells are needed to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> are a type of white blood cell that help prevent <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  Decreased <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Other white blood cells called <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> may also be decreased.</li>
<li>Platelets are blood cells needed for normal blood clotting. Low platelet counts can lead to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  Tell your doctor about any unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
</ul>
</li>
</ul>
<p>Your doctor will check your blood regularly while you are taking TEMODAR to see if these side effects are happening.  Your doctor may need to change the dose of TEMODAR or when you get it depending on your blood cell counts. People who are age 70 or older and women may be more likely to have their blood cells affected.</p>
<ul>
<li>
<span class="Bold Italics">Pneumocystis carinii </span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> (PCP).</span> PCP is an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that people can get when their immune system is weak.  TEMODAR decreases white blood cells, which makes your immune system weaker and can increase your risk of getting PCP. <span class="Bold">All patients</span> taking TEMODAR will be watched carefully by their doctor for this <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, especially patients who take steroids.  Tell your doctor if you have any of the following signs and symptoms of PCP <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and/or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span>.</li>
<li>
<span class="Bold">Secondary cancers.  </span>Blood problems such as <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> and secondary cancers, such as a certain kind of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, can happen in people who take TEMODAR.  Your doctor will watch you for this. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>.  </span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may be severe or life-threatening in people who take TEMODAR.</li>
</ul>
<p>Common side effects with TEMODAR include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  Your doctor can prescribe medicines that may help reduce these symptoms.</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li> feeling tired </li>
<li> loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> on one side of the body</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li> coordination problems</li>
<li><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problems</span></li>
<li> <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, irritation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, warmth, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> at the site of infusion</li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or small red or purple spots under the skin</li>
</ul>
<p>Tell your doctor about any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects with TEMODAR.  For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store TEMODAR Capsules?</span></p>
<ul>
<li>Store TEMODAR Capsules at 77°F (controlled room temperature). Storage at 59° to 86°F (15° to 30°C) is permitted occasionally.</li>
<li><span class="Bold">Keep TEMODAR Capsules out of the reach of children  and pets.</span></li>
</ul>
<p><span class="Bold">General information about TEMODAR.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Package Insert.  Do not use TEMODAR for a condition for which it was not prescribed.  Do not give TEMODAR to other people, even if they have the same symptoms that you have.  It may harm them.</p>
<p>This leaflet summarizes the most important information about TEMODAR.  If you would like more information, talk with your doctor.  You can ask your pharmacist or doctor for information about TEMODAR that is written for health professionals.  </p>
<p>For more information, go to www.TEMODAR.com or call 1-800-526-4099.</p>
<p><span class="Bold">How are TEMODAR Capsules supplied?</span></p>
<p>TEMODAR Capsules contain a white capsule body with a color cap and the colors vary based on the dosage strength. The capsules are available in six different strengths. </p>
<a name="ib205ea3f-556e-4667-820a-0f46265c5fd5"></a><table width="60%">
<col align="left" valign="middle" width="70%">
<col align="left" valign="middle" width="30%">
<thead><tr class="First Last">
<th align="left">TEMODAR Capsule Strength</th>
<th align="left">Color</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">      5 mg</td>
<td align="left">Green Cap</td>
</tr>
<tr>
<td align="left">     20 mg</td>
<td align="left">Yellow Cap</td>
</tr>
<tr>
<td align="left">     100 mg</td>
<td align="left">Pink Cap</td>
</tr>
<tr>
<td align="left">     140 mg</td>
<td align="left">Blue Cap</td>
</tr>
<tr>
<td align="left">     180 mg</td>
<td align="left">Orange Cap</td>
</tr>
<tr class="Last">
<td align="left">     250 mg</td>
<td align="left">White Cap</td>
</tr>
</tbody>
</table>
<p><span class="Bold">What are the ingredients in TEMODAR?   </span></p>
<p><span class="Bold">TEMODAR Capsules:</span></p>
<p>Active ingredient: temozolomide. </p>
<p>Inactive ingredients: lactose anhydrous, colloidal silicon dioxide, sodium starch glycolate, tartaric acid, stearic acid.</p>
<p>The body of the capsules are made of gelatin and are opaque white.  The cap is also made of gelatin, and the colors vary based on the dosage strength.  The capsule body and cap are imprinted with pharmaceutical branding ink, which contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, purified water, strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span>, potassium hydroxide, and ferric oxide.</p>
<p>TEMODAR 5 mg: The green cap contains gelatin, titanium dioxide, iron oxide yellow, sodium lauryl sulfate, and FD&amp;C Blue #2.</p>
<p>TEMODAR 20 mg: The yellow cap contains gelatin, sodium lauryl sulfate, and iron oxide yellow.</p>
<p>TEMODAR 100 mg: The pink cap contains gelatin, titanium dioxide, sodium lauryl sulfate, and iron oxide red.</p>
<p>TEMODAR 140 mg: The blue cap contains gelatin, sodium lauryl sulfate, and FD&amp;C Blue #2.</p>
<p>TEMODAR 180 mg: The orange cap contains gelatin, iron oxide red, iron oxide yellow, titanium dioxide, and sodium lauryl sulfate.</p>
<p>TEMODAR 250mg: The white cap contains gelatin, titanium dioxide, and sodium lauryl sulfate.</p>
<p><span class="Bold">TEMODAR for Injection:</span></p>
<p>Active ingredient: temozolomide.</p>
<p>Inactive ingredients: mannitol, L-threonine, polysorbate 80, sodium citrate dihydrate, and hydrochloric acid. </p>
<p>Issued: February 2009</p>
<p><span class="Underline">TEMODAR Capsules</span><br> Manufactured by: Schering Corporation, a subsidiary of <span class="Bold">{corporate logo}MERCK &amp; CO., INC.</span>, Whitehouse Station, NJ 08889, USA</p>
<p><span class="Underline">TEMODAR for Injection</span><br> Manufactured by: Baxter Oncology GmbH, Halle/Westfalen, Germany <br> Distributed by: Schering Corporation, a subsidiary of <span class="Bold">{corporate logo}MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Copyright©1999, 2008 Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span> All rights reserved.</p>
<p>U.S. Patent Nos. 5,260,291 and 6,987,108.</p>
<p>Rev. 04/10<br>31851114T</p>
<p>The trademarks depicted in this piece are owned by their respective companies.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-19"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PHARMACIST INFORMATION SHEET</span></p>
<p><span class="Bold">What is TEMODAR? </span><span class="Italics">[See <a href="#S1">Full Prescribing Information, Indications and Usage (1)</a>].</span></p>
<p>TEMODAR® (temozolomide) is an alkylating drug for the treatment of adult patients with newly diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span> and refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span>. </p>
<p><span class="Bold">How is TEMODAR dosed?</span><span class="Italics"> [See <a href="#S2.1">Full Prescribing Information, Recommended Dosing and Dose Modification Guidelines (2.1)</a>].</span></p>
<p>The daily dose of TEMODAR for a given patient is calculated by the physician, based on the patient's body surface area (BSA) <span class="Italics">[see <span class="Bold"><a href="#Table-5">Table 5</a></span> in the Full Prescribing Information, Recommended Dosing and Dose Modification Guidelines (2.1)]. </span>The recommended dose for TEMODAR as an intravenous infusion over 90 minutes is the same as the dose for the oral capsule formulation.  Bioequivalence has been established only when TEMODAR for Injection was given over 90 minutes. The dose for subsequent cycles may be adjusted according to nadir neutrophil and platelet counts in the previous cycle and at the time of initiating the next cycle. </p>
<p><span class="Bold">Dosing for Patients with Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span> </span><span class="Italics">[See <a href="#S2.1">Full Prescribing Information, Recommended Dosing and Dose Modification Guidelines, Patients with Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span> (2.1)</a>].</span></p>
<p>Dosage of TEMODAR must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and neutrophil and platelet counts at the time of initiating the next cycle. The initial dose is 150 mg/m<span class="Sup">2</span> orally once daily for 5 consecutive days per 28-day treatment cycle. If both the nadir and day of dosing (Day 29, Day 1 of next cycle) absolute neutrophil counts (ANC) are ≥1.5 × 10<span class="Sup">9</span>/L (1500/µL) and both the nadir and Day 29, Day 1 of next cycle platelet counts are ≥100 × 10<span class="Sup">9</span>/L (100,000/µL), the TEMODAR dose may be increased to 200 mg/m<span class="Sup">2</span>/ day for 5 consecutive days per 28-day treatment cycle. During treatment, a complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 10<span class="Sup">9</span>/L (1500/µL) and the platelet count exceeds 100 × 10<span class="Sup">9</span>/L (100,000/µL). The next cycle of TEMODAR should not be started until the ANC and platelet count exceed these levels. If the ANC <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> to &lt;1.0 × 10<span class="Sup">9</span>/L (1000/µL) or the platelet count is &lt;50 × 10<span class="Sup">9</span>/L (50,000/µL) during any cycle, the next cycle should be reduced by 50 mg/m<span class="Sup">2</span>, but not below 100 mg/m<span class="Sup">2</span>, the lowest recommended dose <span class="Italics">[see <span class="Bold"><a href="#Table-4">Table 4</a></span> in the Full Prescribing Information, Recommended Dosing and Dose Modification Guidelines (2.1)].</span></p>
<p>Patients should continue to receive TEMODAR until their physician determines that their disease has progressed, or until unacceptable side effects or toxicities occur. Physicians may alter the treatment regimen for a given patient.</p>
<p><span class="Bold">Dosing for Patients with Newly Diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">Glioblastoma Multiforme</span> </span><span class="Italics">[See <a href="#S2.1">Full Prescribing Information, Recommended Dosing and Dose Modification Guidelines, Patients with Newly Diagnosed High Grade <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">Glioma</span> (2.1)</a>].</span></p>
<p><span class="Bold">Concomitant Phase Treatment Schedule </span></p>
<p>TEMODAR is administered at 75 mg/m<span class="Sup">2</span> daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions), followed by maintenance TEMODAR for 6 cycles. No dose reductions are recommended; however, dose interruptions may occur based on patient tolerance. The TEMODAR dose can be continued throughout the 42-day concomitant period up to 49 days if all of the following conditions are met: absolute neutrophil count ≥1.5 × 10<span class="Sup">9</span>/L, platelet count ≥100 ×10<span class="Sup">9</span>/L, common toxicity criteria (CTC) non-hematological toxicity ≤ Grade 1 (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>). During treatment a complete blood count should be obtained weekly. Temozolomide dosing should be interrupted or discontinued during concomitant phase according to the hematological and non-hematological toxicity criteria as noted in <span class="Bold"><a href="#Table-1">Table 1</a></span> of the Full Prescribing Information under 2.1 Recommended Dosing and Dose Modification Guidelines. PCP prophylaxis is required during the concomitant administration of TEMODAR and radiotherapy and should be continued in patients who develop <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span> until recovery from <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span> (CTC Grade ≤1).</p>
<p><span class="Bold">Maintenance Phase Treatment Schedule </span></p>
<p>Four weeks after completing the TEMODAR + RT phase, TEMODAR is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m<span class="Sup">2 </span>once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose can be escalated to 200 mg/m<span class="Sup">2</span>, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>), absolute neutrophil count (ANC) is ≥1.5 × 10<span class="Sup">9</span>/L, and the platelet count is ≥100 × 10<span class="Sup">9</span>/L.  If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.  The dose remains at 200 mg/m<span class="Sup">2</span> per day for the first 5 days of each subsequent cycle except if toxicity occurs.</p>
<p>During treatment a complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 10<span class="Sup">9</span>/L (1500/µL) and the platelet count exceeds 100 × 10<span class="Sup">9</span>/L (100,000/µL). The next cycle of TEMODAR should not be started until the ANC and platelet count exceed these levels.  Dose reductions during the next cycle should be based on the lowest blood counts and worst nonhematologic toxicity during the previous cycle. Dose reductions or discontinuations during the maintenance phase should be applied according to <span class="Bold"><a href="#Table-2">Tables 2 </a></span> and <span class="Bold"><a href="#Table-3">3</a></span> in the Full Prescribing Information under 2.1 Recommended Dosing and Dose Modification Guidelines.</p>
<p><span class="Bold">How is TEMODAR for Injection prepared?</span><span class="Italics"> [See <a href="#S2.2">Full Prescribing Information, Preparation and Administration, TEMODAR for Injection (2.2)</a>].</span></p>
<p>Care should be exercised in the handling and preparation of TEMODAR. Vials should not be opened. If vials are accidentally opened or damaged, rigorous precautions should be taken with the contents to avoid inhalation or contact with the skin or mucous membranes.  The use of gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial.  Procedures for proper handling and disposal of anticancer drugs should be considered<span class="Sup">1–4</span>.  Several guidelines on this subject have been published.  </p>
<ol>
<li>TEMODAR for Injection vials should be stored refrigerated at 2°–8°C (36°–46°F). </li>
<li>Bring the vial to room temperature prior to reconstitution with Sterile Water for Injection.</li>
<li>Using aseptic technique, reconstitute each vial with 41 mL Sterile Water for Injection. The resulting solution will contain 2.5 mg/mL temozolomide.</li>
<li>Vial should be gently swirled and not shaken.  Inspect vials, and any vial containing visible particulate matter should not be used. Do not further dilute the reconstituted solution. Upon reconstitution, store at room temperature for up to 14 hours, including infusion time. </li>
<li>Using aseptic technique, withdraw up to 40 mL from each vial to make up the total dose and transfer into an empty 250 mL infusion bag.</li>
<li>Attach the pump tubing to the bag, purge the tubing and then cap. </li>
</ol>
<p><span class="Bold">How is TEMODAR for Injection administered?</span><span class="Italics"> [See <a href="#S2.2">Full Prescribing Information, Preparation and Administration, TEMODAR for Injection (2.2)</a>].</span></p>
<p>TEMODAR for Injection is administered as an intravenous infusion over 90 minutes.  Bioequivalence has been established only when TEMODAR for Injection was given over 90 minutes.  TEMODAR for Injection should be administered only by intravenous infusion. Flush the lines before and after each TEMODAR infusion.</p>
<p>TEMODAR for Injection may be administered in the same intravenous line with 0.9% Sodium Chloride injection only.</p>
<p>Because no data are available on the compatibility of TEMODAR for Injection with other intravenous substances or additives, other medications should not be infused simultaneously through the same intravenous line.</p>
<p><span class="Bold">What should the patient avoid during treatment with TEMODAR? </span><span class="Italics">[See <a href="#S8.1">Full Prescribing Information, Use in Specific Populations, Pregnancy (8.1)</a> and <a href="#S8.3">Nursing Mothers (8.3)</a>].</span></p>
<p>There are no dietary restrictions for patients taking TEMODAR. TEMODAR may affect testicular function, so male patients should exercise adequate birth control measures. TEMODAR may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.  Female patients should avoid becoming pregnant while receiving this drug. It is not known whether TEMODAR is excreted into breast milk.  Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants and tumorigenicity shown for temozolomide in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother from TEMODAR.  </p>
<p><span class="Bold">What are the side effects of TEMODAR?</span><span class="Italics"> [See <a href="#S6">Full Prescribing Information, Adverse Reactions (6)</a>].</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are the most common side effects associated with TEMODAR. Noncumulative <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is the dose-limiting toxicity. Patients should be evaluated periodically by their physician to monitor blood counts.</p>
<p><span class="Bold">Other commonly reported side effects reported by patients taking TEMODAR </span>are <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, as well as <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, irritation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, warmth, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> at the site of infusion. </p>
<p><span class="Bold">How is TEMODAR supplied? </span><span class="Italics">[See <a href="#S16">Full Prescribing Information, How Supplied/Storage and Handling (16)</a>].</span></p>
<p>TEMODAR for Injection is supplied in single-use glass vials containing 100 mg temozolomide. TEMODAR is also available as capsules in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths.  </p>
<ol>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. </li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm.</span> 2006; 63:1172–1193.</li>
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.[3]  </li>
<li>Polovich, M., White, J. M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology.</li>
</ol>
<p><span class="Underline">TEMODAR for Injection</span><br> Manufactured by: Baxter Oncology GmbH, Halle/Westfalen, Germany<br>Distributed by: Schering Corporation, a subsidiary of <span class="Bold">{corporate logo}MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Copyright© 2008 Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span> All rights reserved.</p>
<p>U.S. Patent Nos. 5,260,291, 6,987,108, and 7,786,118.</p>
<p>Rev. 2/11 <br>30984447T</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-20"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PHARMACIST:</span></p>
<p>									Tear at perforation and give to patient.</p>
<p><span class="Bold">PHARMACIST INFORMATION SHEET</span></p>
<div class="Warning">
<a name="section-20.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">IMPORTANT DISPENSING INFORMATION</span></p>
<p><span class="Bold">For every patient, TEMODAR must be dispensed in a separate vial or in its original glass bottle making sure each container lists the strength per capsule and that patients take the appropriate number of capsules from each bottle or vial.</span></p>
<p><span class="Bold">Please see the dispensing instructions below for more information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-20.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">What is TEMODAR?</span></p>
<p>TEMODAR<span class="Sup">®</span> (temozolomide) is an oral alkylating agent for the treatment of newly diagnosed <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span> and refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span>.</p>
<p><span class="Bold">How is TEMODAR dosed?</span></p>
<p>The daily dose of TEMODAR Capsules for a given patient is calculated by the physician, based on the patient's body surface area (BSA). The resulting dose is then rounded off to the nearest 5 mg. An example of the dosing may be as follows: the initial daily dose of TEMODAR in milligrams is the BSA multiplied by mg/m<span class="Sup">2</span>/day, (a patient with a BSA of 1.84 is 1.84 × 75 mg = 138, or 140 mg/day). The dose for subsequent cycles may be adjusted according to nadir neutrophil and platelet counts in the previous cycle and at the time of initiating the next cycle.</p>
<p><span class="Bold">How might the dose of TEMODAR be modified for Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span>?</span></p>
<p>Dosage of TEMODAR must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and neutrophil and platelet counts at the time of initiating the next cycle. The initial dose is 150 mg/m<span class="Sup">2</span> orally once daily for 5 consecutive days per 28-day treatment cycle. If both the nadir and day of dosing (Day 29, Day 1 of next cycle) absolute neutrophil counts (ANC) are ≥1.5 × 10<span class="Sup">9</span>/L (1500/µL) and both the nadir and Day 29, Day 1 of next cycle platelet counts are ≥100 × 10<span class="Sup">9</span>/L (100,000/µL), the TEMODAR dose may be increased to 200 mg/m<span class="Sup">2</span>/ day for 5 consecutive days per 28-day treatment cycle. During treatment, a complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 10<span class="Sup">9</span>/L (1500/µL) and the platelet count exceeds 100 × 10<span class="Sup">9</span>/L (100,000/µL). The next cycle of TEMODAR should not be started until the ANC and platelet count exceed these levels. If the ANC <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> to &lt;1.0 × 10<span class="Sup">9</span>/L (1000/µL) or the platelet count is &lt;50 × 10<span class="Sup">9</span>/L (50,000/µL) during any cycle, the next cycle should be reduced by 50 mg/m<span class="Sup">2</span>, but not below 100 mg/m<span class="Sup">2</span>, the lowest recommended dose (see <span class="Bold"><a href="#SPM-t1">Table 1</a></span> below).</p>
<a name="SPM-t1"></a><table width="100%">
<caption><span>TABLE 1: Dosing Modification Table for Refractory <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">Anaplastic Astrocytoma</span></span></caption>
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="Botrule First Last Toprule"><td align="center"><img alt="Table" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=temodar-04.jpg"></td></tr></tbody>
</table>
<p><span class="Bold">What is the TEMODAR Capsules treatment regimen?</span></p>
<p>TEMODAR is given for 5 consecutive days on a 28-day cycle. Patients should continue taking TEMODAR until their physician determines that their disease has progressed, up to 2 years, or until unacceptable side effects or toxicities occur. Physicians may alter the treatment regimen for a given patient.</p>
<p><span class="Bold">Newly Diagnosed Concomitant Phase Treatment Schedule</span></p>
<p>TEMODAR is administered orally at 75 mg/m<span class="Sup">2</span> daily for 42 days concomitant with focal radiotherapy (60Gy administered in 30 fractions), followed by maintenance TEMODAR for 6 cycles. No dose reductions are recommended; however, dose interruptions may occur based on patient tolerance. The TEMODAR dose can be continued throughout the 42-day concomitant period up to 49 days if all of the following conditions are met: absolute neutrophil count ≥1.5 × 10<span class="Sup">9</span>/L, platelet count ≥100 ×10<span class="Sup">9</span>/L, common toxicity criteria (CTC) nonhematological toxicity ≤Grade 1 (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>). During treatment a complete blood count should be obtained weekly. Temozolomide dosing should be interrupted or discontinued during concomitant phase according to the hematological and nonhematological toxicity criteria as noted in <span class="Bold"><a href="#SPM-t2">Table 2.</a></span> PCP prophylaxis is required during the concomitant administration of TEMODAR and radiotherapy and should be continued in patients who develop <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span> until recovery from <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span> (CTC grade ≤1).</p>
<a name="SPM-t2"></a><table width="75%">
<caption><span>TABLE 2: Temozolomide Dosing Interruption or Discontinuation During Concomitant Radiotherapy and Temozolomide</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Toxicity</th>
<th class="Rrule" align="center">TMZ Interruption<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>
</th>
<th class="Rrule" align="center">TMZ Discontinuation</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">TMZ = temozolomide; CTC = Common Toxicity Criteria.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Treatment with concomitant TMZ could be continued when all of the following conditions were met: absolute neutrophil count ≥1.5 × 10<span class="Sup">9</span>/L; platelet count ≥100 × 10<span class="Sup">9</span>/L; CTC non-hematological toxicity ≤Grade 1 (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>).</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Absolute Neutrophil Count</td>
<td class="Rrule" align="center">≥0.5 and &lt;1.5 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">&lt;0.5 × 10<span class="Sup">9</span>/L</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Platelet Count</td>
<td class="Rrule" align="center">≥10 and &lt;100 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">&lt;10 × 10<span class="Sup">9</span>/L</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">CTC Nonhematological Toxicity (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>)</td>
<td class="Rrule" align="center" valign="bottom">CTC Grade 2</td>
<td class="Rrule" align="center" valign="bottom">CTC Grade 3 or 4</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Maintenance Phase Treatment Schedule </span></p>
<p>Four weeks after completing the TEMODAR + RT phase, TEMODAR is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m<span class="Sup">2 </span>once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200 mg/m<span class="Sup">2 </span>, if the CTC nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>), absolute neutrophil count (ANC) is ≥1.5 × 10<span class="Sup">9</span>/L, and the platelet count is ≥100 × 10<span class="Sup">9</span>/L. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles. The dose remains at 200 mg/m<span class="Sup">2</span> per day for the first 5 days of each subsequent cycle except if toxicity occurs.</p>
<p>During treatment a complete blood count should be obtained on Day 22 (21 days after the first dose ) or within 48 hours of that day, and weekly until the ANC is above 1.5 × 10<span class="Sup">9</span>/L (1500/µL) and the platelet count exceeds 100 × 10<span class="Sup">9</span>/L (100,000/µL). The next cycle of TEMODAR should not be started until the ANC and platelet count exceed these levels. Dose reductions during the next cycle should be based on the lowest blood counts and worst nonhematologic toxicity during the previous cycle. Dose reductions or discontinuations during the maintenance phase should be applied according to Tables <span class="Bold"><a href="#SPM-t3">3</a> and <a href="#SPM-t4">4</a></span>.</p>
<a name="SPM-t3"></a><table width="75%">
<caption><span>TABLE 3: Temozolomide Dose Levels for Maintenance Treatment</span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Dose Level</th>
<th class="Rrule" align="center">Dose (mg/m<span class="Sup">2</span>/day)</th>
<th class="Rrule" align="center">Remarks</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">−1</td>
<td class="Rrule" align="center">100</td>
<td class="Rrule" align="left">Reduction for prior toxicity</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">0</td>
<td class="Rrule" align="center">150</td>
<td class="Rrule" align="left">Dose during Cycle 1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">200</td>
<td class="Rrule" align="left">Dose during Cycles 2–6 in absence of toxicity</td>
</tr>
</tbody>
</table>
<a name="SPM-t4"></a><table width="75%">
<caption><span>TABLE 4: Temozolomide Dose Reduction or Discontinuation During Maintenance Treatment</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Toxicity</th>
<th class="Rrule" align="center">Reduce TMZ by 1 Dose Level<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Discontinue TMZ</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">TMZ = temozolomide; CTC = Common Toxicity Criteria.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>TMZ dose levels are listed in Table 3.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>TMZ is to be discontinued if dose reduction to &lt;100 mg/m<span class="Sup">2</span> is required or if the same Grade 3 nonhematological toxicity (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>) recurs after dose reduction.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Absolute Neutrophil Count</td>
<td class="Rrule" align="center">&lt;1.0 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">See footnote <a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Platelet Count</td>
<td class="Rrule" align="center">&lt;50 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">See footnote <a href="#footnote-10" class="Sup">†</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">CTC Nonhematological Toxicity<br> (except for <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>)</td>
<td class="Rrule" align="center" valign="bottom">CTC Grade 3</td>
<td class="Rrule" align="center" valign="bottom">CTC Grade 4<a href="#footnote-10" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">How is TEMODAR taken?</span></p>
<p>Patients should take each day's dose with a full glass of water at the same time each day. Taking the medication on an empty stomach or at bedtime may help ease <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. If patients are also taking antinausea or other medications to relieve the side effects associated with TEMODAR, they should be advised to take these medications 30 minutes before they take TEMODAR. Temozolomide causes the rapid appearance of <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> in rats. Patients <span class="Bold">SHOULD NOT </span>open or split the capsules. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes. The medication should be kept away from children and pets. The TEMODAR capsules should be swallowed whole and <span class="Bold">NEVER CHEWED</span>.</p>
<p><span class="Bold">What should the patient avoid during treatment with TEMODAR?</span></p>
<p>There are no dietary restrictions for patients taking TEMODAR. TEMODAR may affect testicular function, so male patients should exercise adequate birth control measures. TEMODAR may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Female patients should avoid becoming pregnant while receiving this drug. Women who are nursing prior to receiving TEMODAR should discontinue nursing. It is not known whether TEMODAR is excreted into breast milk.</p>
<p><span class="Bold">What are the side effects of TEMODAR?</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are the most common side effects associated with TEMODAR. Noncumulative <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is the dose-limiting toxicity. Patients should be evaluated periodically by their physician to monitor blood counts.</p>
<p><span class="Bold">Other commonly reported side effects reported by patients taking TEMODAR </span>are <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><span class="Bold">How is TEMODAR supplied?</span></p>
<p>TEMODAR Capsules are available in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths. The capsules contain a white capsule body with a color cap, and the colors vary based on the dosage strength.</p>
<a name="i86853231-63ee-478c-8005-f4cede6783a7"></a><table width="50%">
<col align="center" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<thead><tr class="First Last">
<th align="center">TEMODAR Capsule Strength</th>
<th align="left">Color</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">5 mg</td>
<td align="left">Green Cap</td>
</tr>
<tr>
<td align="center"> 20 mg</td>
<td align="left">Yellow Cap</td>
</tr>
<tr>
<td align="center">100 mg</td>
<td align="left">Pink Cap</td>
</tr>
<tr>
<td align="center">140 mg</td>
<td align="left">Blue Cap</td>
</tr>
<tr>
<td align="center">180 mg</td>
<td align="left">Orange Cap</td>
</tr>
<tr class="Last">
<td align="center">250 mg</td>
<td align="left">White Cap</td>
</tr>
</tbody>
</table>
<p>The 5-mg, 20-mg, 100-mg, 140-mg, and 180-mg capsule strengths are available in 5-count and 14-count packages. The 250-mg capsule strength is available in a 5-count package. </p>
<p><span class="Bold">How is TEMODAR dispensed?</span></p>
<p>Each strength of TEMODAR must be dispensed in a separate vial or in its original glass bottle (one strength per one container).  Follow the instructions below:</p>
<p>Based on the dose prescribed, determine the number of each strength of TEMODAR capsules needed for the full 42- or 5-day cycle as prescribed by the physician.  For example, in a 5-day cycle, 275 mg/day would be dispensed as five 250-mg capsules, five 20-mg capsules and five 5-mg capsules.  Label each container with the appropriate number of capsules to be taken each day.  Dispense to the patient, making sure each container lists the strength (mg) per capsule and that he or she understands to take the appropriate number of capsules of TEMODAR from each bottle or vial to equal the total daily dose prescribed by the physician.</p>
<p><span class="Bold">How can TEMODAR be ordered?</span></p>
<p>TEMODAR can be ordered from your wholesaler. It is important to understand if TEMODAR is being used as part of a 42-day regimen or as part of a 5-day course. Remember to order enough TEMODAR for the appropriate cycle.</p>
<p>For example:</p>
<ul>
<li>a 5-day course of 360 mg/day would require the following to be ordered: two 5-count packages of 180-mg capsules.</li>
<li>a 42-day course of 140 mg/day would require the following to be ordered: three 14-count packages of 140-mg capsules.</li>
</ul>
<p>For examples of other dosing regimens, please refer to the full Prescribing Information (Table 10)</p>
<a name="if793708f-ed71-4de2-8f84-cab1a1deb7b0"></a><table width="50%">
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="40%">
<thead><tr class="First Last">
<th class="Lrule" align="left">TEMODAR Product</th>
<th class="Rrule" align="center">NDC Number</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">5-mg capsules (5 count)</td>
<td class="Rrule" align="center">0085-3004-02</td>
</tr>
<tr>
<td class="Lrule" align="left">5-mg capsules (14 count)</td>
<td class="Rrule" align="center">0085-3004-01</td>
</tr>
<tr>
<td class="Lrule" align="left">20-mg capsules (5 count)</td>
<td class="Rrule" align="center">0085-1519-02</td>
</tr>
<tr>
<td class="Lrule" align="left">20-mg capsules (14 count)</td>
<td class="Rrule" align="center">0085-1519-01</td>
</tr>
<tr>
<td class="Lrule" align="left">100-mg capsules (5 count)</td>
<td class="Rrule" align="center">0085-1366-02</td>
</tr>
<tr>
<td class="Lrule" align="left">100-mg capsules (14 count)</td>
<td class="Rrule" align="center">0085-1366-01</td>
</tr>
<tr>
<td class="Lrule" align="left">140-mg capsules (5 count)</td>
<td class="Rrule" align="center">0085-1425-01</td>
</tr>
<tr>
<td class="Lrule" align="left">140-mg capsules (14 count)</td>
<td class="Rrule" align="center">0085-1425-02</td>
</tr>
<tr>
<td class="Lrule" align="left">180-mg capsules (5 count)</td>
<td class="Rrule" align="center">0085-1430-01</td>
</tr>
<tr>
<td class="Lrule" align="left">180-mg capsules (14 count)</td>
<td class="Rrule" align="center">0085-1430-02</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">250-mg capsules (5 count)</td>
<td class="Rrule" align="center">0085-1417-01</td>
</tr>
</tbody>
</table>
<p>Manufactured by: Schering Corporation, a subsidiary of <span class="Bold">{corporate logo}MERCK&amp; CO., INC.</span>, Whitehouse Station, NJ 08889 USA</p>
<p>Copyright© 2005 Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span> All rights reserved.<br>U.S. Patent No. 5,260,291. <br>33276915T<br> Rev. 4/10<br><br><br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg Capsule<br></span></p>
<p><span class="Bold">5 mg<br>per capsule</span></p>
<p><span class="Bold">Temodar<span class="Sup">®</span></span><br>(temozolomide)<br>Capsules</p>
<p><span class="Bold">For Oral Administration<br>Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg Capsule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=5348.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 20 mg Capsule<br></span></p>
<p><span class="Bold">20 mg<br>per capsule</span></p>
<p><span class="Bold">Temodar<span class="Sup">®</span></span><br>(temozolomide)<br>Capsules</p>
<p><span class="Bold">For Oral Administration<br>Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Capsule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=4142.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg Capsule<br></span></p>
<p><span class="Bold"></span><br><span class="Bold">100 mg<br>per capsule</span></p>
<p><span class="Bold">Temodar<span class="Sup">®</span></span><br>(temozolomide)<br>Capsules</p>
<p><span class="Bold">For Oral Administration<br>Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mg Capsule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=5350.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-24"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 180 mg Capsule<br></span></p>
<p><span class="Bold">180 mg<br>per capsule</span></p>
<p><span class="Bold">Temodar<span class="Sup">®</span></span><br>(temozolomide)<br>Capsules</p>
<p><span class="Bold">For Oral Administration<br>Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 180 mg Capsule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=5980.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-25"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 250 mg Capsule<br></span></p>
<p><span class="Bold">250 mg<br>per capsule</span></p>
<p><span class="Bold">Temodar<span class="Sup">®</span></span><br>(temozolomide)<br>Capsules</p>
<p><span class="Bold">For Oral Administration<br>Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 250 mg Capsule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf&amp;name=5354.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TEMODAR 		
					</strong><br><span class="contentTableReg">temozolomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5348(NDC:0085-3004)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Temozolomide</strong> (Temozolomide) </td>
<td class="formItem">Temozolomide</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>tartaric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEMODAR;5;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5348-1</td>
<td class="formItem">5  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021029</td>
<td class="formItem">10/20/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TEMODAR 		
					</strong><br><span class="contentTableReg">temozolomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4142(NDC:0085-1519)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Temozolomide</strong> (Temozolomide) </td>
<td class="formItem">Temozolomide</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>tartaric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEMODAR;20;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4142-0</td>
<td class="formItem">5  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4142-2</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4142-3</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-4142-4</td>
<td class="formItem">40  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-4142-5</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:54868-4142-6</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021029</td>
<td class="formItem">06/29/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TEMODAR 		
					</strong><br><span class="contentTableReg">temozolomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5350(NDC:0085-1366)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Temozolomide</strong> (Temozolomide) </td>
<td class="formItem">Temozolomide</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>tartaric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEMODAR;100;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5350-0</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5350-2</td>
<td class="formItem">5  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5350-3</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-5350-4</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021029</td>
<td class="formItem">10/07/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TEMODAR 		
					</strong><br><span class="contentTableReg">temozolomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5980(NDC:0085-1430)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Temozolomide</strong> (Temozolomide) </td>
<td class="formItem">Temozolomide</td>
<td class="formItem">180 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>tartaric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEMODAR;180;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5980-0</td>
<td class="formItem">14  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021029</td>
<td class="formItem">01/26/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TEMODAR 		
					</strong><br><span class="contentTableReg">temozolomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5354(NDC:0085-1417)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Temozolomide</strong> (Temozolomide) </td>
<td class="formItem">Temozolomide</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>tartaric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEMODAR;250;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5354-0</td>
<td class="formItem">5  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021029</td>
<td class="formItem">04/13/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cef15d8b-d8c6-491e-9549-695ddc33892b</div>
<div>Set id: 819571ea-b808-4fd8-93c7-1ea2e33d71cf</div>
<div>Version: 1</div>
<div>Effective Time: 20110209</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
